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Abbreviations 
 
2D:    two-dimensional 
3D:    three-dimensional 
ADME:  Absorption, distribution, metabolism, excretion 
AP:    Attachment point 
DOGS:  Design of genuine structures 
EA:    Evolutionary algorithm 
ER:    Estrogen receptor 
FEP:    Free energy perturbation 
FGA:    Functional group addition 
FGI:    Functional group interconversion 
GPCR:   G-protein coupled receptor 
hH4R    Human histamine H4-receptor 
HIV-RT:  Human immunodeficiency virus reverse transcriptase 
HTS:    High throughput screening 
mg:    Molecular graph 
NCE:    New/novel chemical entity 
PSO:    Particle swarm optimization 
QSAR:    Quantitative structure activity relationship 
SSSR:   Smallest set of smallest rings 
TGF:    Transforming growth factor 
rg:    Reduced graph 
VS:    Virtual screening 
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1 Introduction 
 
One of the early and pivotal steps in drug development is the identification of structurally 
novel chemical entities (NCE) exhibiting a desired effect on a biological target molecule. 
Identification of NCEs may be approached by two complementary strategies: One can either 
search for NCEs in libraries of already existing small organic molecules (high throughput 
screening, HTS) or synthesize new molecules ‘from scratch’ that are tailored for a particular 
project (de novo design). Both strategies have their advantages and caveats. While the costs 
per tested molecule are typically of magnitudes lower for HTS than for de novo designed 
compounds,
1 HTS is limited to known regions of the chemical space. This can be a problem 
in case a HTS library does not contain appropriate molecules for the project at hand. In 
contrast,  de  novo  design  holds  the  appealing  advantage  to  be  theoretically  unlimited  and 
intrinsically innovative. On the other hand, custom synthesis of small organic molecules is 
comparably  slow  and  more  expensive. T h e  two  strategies  can  therefore  be  seen  as 
complementary and can be employed in parallel in drug development campaigns. 
Since the 1950s computer-assisted methods have found entrance to the drug development 
process.
2 For both strategies (HTS and de novo synthesis) in silico counterparts have been 
introduced to complement and support the traditional drug development methods. Like HTS, 
software for virtual screening (VS) evaluates large collections of available compounds with 
respect  to  their  potential  biological  activity.  A  plethora  of  different  approaches  has  been 
proposed for this purpose.
2,3 Programs for computer-assisted de novo design suggest novel 
compounds supposed to possess desired pharmacological properties (Figure 1). 
 
 
Figure 1. Computational counterparts for conventional drug development methods have 
been introduced throughout the last decades. 
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The goal of this work is the development of a new program for computer-assisted de novo 
design of drug candidate compounds. 
 
1.1  Computer-assisted  De  Novo D e s i g n  o f  D r u g  C a n d i d a t e  
Structures 
The first programs for computer-assisted de novo design (termed ‘de novo design’ in the 
following) were published about 20 years ago in the late 1980s.
4 Table 1 presents an overview 
of  existing  computer  programs  for  molecular  de  novo  design.  Software  tools  can  be 
categorized by the strategies applied to address three pivotal elements of molecule design: 
 
1.  How is the quality of proposed molecules assessed (scoring strategy)? 
2.  How are molecules constructed (assembly strategy)? 
3.  How does the optimization progress based on the current state of knowledge (search 
strategy)? 
 
Regardless of the way different approaches try to solve these challenges, almost all of them 
follow the fundamental concept to mimic the iterative process of drug discovery research in a 
real laboratory: molecules are generated, subsequently tested, and the results form the basis of 
the next round of synthesis. Search and assembly strategies correspond to the intellectual and 
technical  work  of  a  chemist,  whereas  scoring  complies  with  testing  the  compounds  for 
activity in a biological assay. 
 
Table 1. Chronological overview of de novo design software and the applied type of scoring strategy. 
If available, a software name is given. Otherwise, the name of the first author is used (table continues 
on the next page).  
    Scoring 
Method/Name 
Year of 
publication 
Ligand-
based 
Receptor-
based 
HSITE/2D Skeletons
5-7  1989    X 
3D Skeletons
8  1990    X 
Builder v1
9  1992    X 
LUDI
10-14  1992    X 
NEWLEAD
15  1993    X 
SPLICE
16  1993    X 
GroupBuild
17  1993    X 
CONCEPTS
18  1993    X 
SPROUT
19-22  1993    X 
MCSS & HOOK
23,24  1994    X 
GrowMol
25  1994    X 
Chemical Genesis
26  1995  X  X 	
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PRO_LIGAND
27-32  1995  X  X 
SMoG
33-35  1996    X 
CONCERTS
36  1996    X 
PRO_SELECT
37,38  1997    X 
Skelgen
39-44  1997  X  X 
Nachbar
45,46  1998  X   
Globus
47  1999  X   
DycoBlock
48-49  1999    X 
LEA
50  2000  X   
LigBuilder
51  2000    X 
TOPAS
52,53  2000  X   
F-DycoBlock
54  2001    X 
ADAPT
55  2001    X 
Pellegrini & Field
56  2003  X  X 
SYNOPSIS
57  2003    X 
CoG
58  2004  X   
BREED
59  2004  X   
Nikitin
60  2005    X 
LEA3D
61  2005    X 
Flux
62,63  2006  X   
FlexNovo
64  2006    X 
BOMB
65  2006    X 
Feher
66  2008  X   
GANDI
67  2008  X  X 
COLIBREE
68  2008  X   
SQUIRRELnovo
69,70  2009  X   
Hecht&Fogel
71  2009  X  X 
FOG
72  2009  X   
MED-Hybridise
73  2009    X 
MEGA
74  2009  X  X 
Fragment Shuffling
75  2009  X  X 
AutoGrow
76  2009    X 
BI CLAIM
77  2009  X   
NovoFLAP
78  2010  X   
PhDD
79  2010  X   
GARLig
80  2010    X 
DOGS
81  2011  X   
 
1.1.1 Scoring Strategies 
Early de novo design programs were exclusively based on receptor-based scoring schemes, 
i.e. the quality of proposed molecules is assessed by evaluating their potential to interact with 
a binding site on the receptor surface. This approach is limited to target proteins for which 
data about their three-dimensional (3D) structure is available, which is not the case for all 
targets  of  pharmaceutical  relevance.  For  example,  G-protein  coupled  receptors  (GPCR) 
represent a target class of high interest for the pharmaceutical industry
82 for which only little 
experimental data about 3D structures of its members could be collected so far.
83 Receptor-
based  tools  were  therefore  soon  augmented  by  the  development  of  ligand-based  scoring 
schemes to circumvent this shortcoming (Table 1). While receptor-based scoring relies on the 	
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concept  of  complementarity  to  the  binding  pocket,  ligand-based  scoring  schemes  assess 
similarity (or distance) to known reference ligands exhibiting the desired biological activity. 
Following the ‘similarity principle’ stated by Johnson and Maggiora
84 compounds designed 
under  the  objective  to  show  high  structural  similarity  to  the  reference  should  have  an 
increased probability to exhibit similar pharmacological properties. 
 
Receptor-based scoring 
Receptor-based  approaches  are  closely  related  to  computational  strategies  for  molecular 
docking.  While  docking  tries  to  place  complete  ligands  into  a  binding  pocket,  de  novo 
strategies  construct  the  compound  directly  within  the  cavity ( in  situ  construction).  Both 
techniques share the objective to maximize the complementarity of the ligand to the binding 
site regarding shape and properties. Common approaches to estimate the quality of binding 
during the design process are therefore the same as for molecular docking, where three main 
strategies have emerged: (i) molecular force fields, (ii) empirical scoring functions, and (iii) 
knowledge-based scoring functions.
85,86  
Force fields treat molecules as ensembles of balls (atoms) connected by springs (bonds). Each 
spring has optimal values for length, torsion angles and angles to other springs. Deviation 
from these optimal values result in strain. Accordingly, low strain energies correspond to 
favorable ligand conformations. Interaction with the receptor molecule is estimated by two 
terms  for  non-bonded  interactions  (Coulomb  and  van-der-Waals  potentials,  sometimes 
augmented by an explicit term for contributions of hydrogen bonds). A generalized force field 
term for non-covalent interactions is given in equation (1). It computes their contribution E to 
the binding energy between a ligand and a receptor for a given binding mode as 
 
€ 
E =
Aij
r
12 −
Bij
r
6 +
qiq j
Drij
⊡ 
⊣ 
⊢ 
⊤ 
⊦ 
⊥ 
j=1
rec ∑
i=1
lig ∑ ,              (1) 
 
where  Aij  and  Bij  are  parameters  expressing  repulsion  and  attraction  of  van-der-Waals 
interactions of atoms i and j at a distance rij, qi is a is the point charge of atom i and D is the 
dielectric  constant  of  the  solvent.
86  For  example,  the  docking  software  GOLD  uses a  
molecular mechanics scoring function in its original implementation.
87,88 
Empirical  scoring  functions  are  weighted  sums  of  several  separate  components,  where 
weights are determined by regression analysis. Weights are optimized in order to reproduce 
experimentally  measured  activity  values  of  known  ligand-receptor  complexes.  Individual 	
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components represent different ligand-receptor interactions, which can be determined from a 
given binding pose. An example of a docking software implementing an empirical scoring 
function is FlexX.
89 The free energy of binding is calculated as presented in equation (2) 
(generalized from an example given in reference 86). 
 
 
€ 
ΔG = ΔG0 ΔGi *counti * peni [ ]
i=1
#it ∑ ,              (2) 
 
where ΔGi represents the contribution (adjusted weight) of interaction type i, counti is the 
number of times this interaction type (it) is observed in the given receptor-ligand complex and 
peni is a penalty function accounting for deviations from the ideal interaction geometries for 
some interaction types like e.g. hydrogen bonds, salt bridges or aromatic interactions. The 
penalty must be evaluated for each observed interaction of such a type and is summarized in 
peni for all instances of an interaction type. ΔG0 is a fixed ground term that is also adjusted 
during the fitting process. 
Knowledge-based scoring functions rely on discrepancies between observable and expected 
distributions of atom pair occurrences. Based on the frequencies of atoms one can calculate a 
background probability of the chance that two atoms (one from the receptor and one from the 
ligand) are placed in a certain distance in a random ligand-receptor complex, given that they 
do not interact. This is compared to the counts of atom pairs observed in experimentally 
explored  ligand-receptor  complexes  (training  set)  and  finally  transformed  into  interaction 
scores by an inverse formulation of the Boltzmann law.
85 Atom pairs that occur in higher 
frequencies than expected by chance result in negative interaction energies (attraction) while 
less frequently observed pairs score positive (repulsion). Ligand affinity in a given complex 
with a receptor is estimated by summing up individual scores of observed atom pairs derived 
from the training set. DrugScore
90,91 is an example for a knowledge-based scoring function 
for molecular docking. Equation (3) calculates the contribution of atom pairs between atom 
types i and j at distance r to the interaction energy of the ligand-receptor complex.
86  
 
 
€ 
E(i, j) = −kBTlngij(r),                (3) 
 
where kB is the Boltzmann constant, T is the absolute temperature and function gij is a quotient 
of observed and background frequencies of atom pairs of type i and j at distance r. The total 
energy of binding is calculated as a sum of these terms for all pairs of atom types and a range 
of different distances. 	
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Ligand-based scoring 
In contrast to computing the complementarity of ligands with the binding site, ligand-based 
scoring  schemes  compare  ligand  candidates  to  a  reference  compound  exhibiting  desired 
properties and compute a similarity index (or the distance) between them in a descriptor 
space. For this purpose, the compounds have to be encoded by a mathematical representation 
allowing for efficient comparison. The concept of similarity also forms the basis of ligand-
based virtual screening methods. As a consequence, almost every type of technique developed 
for VS also finds application in de novo design. For ligand comparison, a model representing 
the molecules and a metric measuring distances in the space of the model need to be selected. 
While  receptor-based  scoring  inevitably  requires  accounting  for  3D  conformations  of 
designed compounds, ligand-based approaches can also work on models based on topological 
2D structures (an example for a de novo design software working on 2D representations is 
TOPAS
52,53). T his  can  be  of  particular  interest  if  no  sound  hypotheses  about  the  binding 
modes of reference ligands exist or computational power and run time need to be saved.  
Several  ligand  based  de  novo  design  programs  use  pharmacophore  models  for  quality 
assessment.  These  methods  compare  molecules  by  the  topological  (2D
62,63)  or  spatial 
(3D
69,70,78)  arrangement  of  potential  interaction  centers.  Even  straighforward  substructure 
fingerprints accounting for the presence and absence of certain structural motifs have found 
application  in  de  novo  scoring  strategies.
52,53  Some  tools  also  employ  pseudoreceptor 
techniques
92 and related methods like molecular field analysis (MFA
28) for scoring. These 
approaches calculate pharmacophoric and steric constraints of a hypothetical receptor pocket 
based on a 3D conformation of an active ligand and assess the score of a new compound by 
evaluating its complementarity to this cavity model, forming a bridge between receptor- and 
ligand-based  methods.
93  Ligand-based  scoring  strategies  can  either  be  based  on  a  single 
reference or an ensemble of known ligands. For example, a consensus pharmacophore model 
can be built from a multiple alignment of reference ligands. Some scoring techniques even 
require  a  whole  set  of  known  actives:  QSAR  (quantitative  structure  activity  relationship) 
methods correlate biological activities of training set compounds with calculated descriptors 
to yield a predictive model for activity.
56 
 
1.1.2 Assembly Strategies 
Compound  assembly  strategies  can  be  subdivided  into  atom-based  and  fragment-based 
approaches.  Atom-based  techniques  build  up  new  molecules  atom  by  atom,  whereas 	
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fragment-based design relies on molecular fragments as building blocks. A fragment can be 
anything from a single atom to a polycyclic ring system. Most of the early de novo design 
tools were strictly atom-based. Modern approaches often provide a diverse selection of large 
and small virtual molecular entities for compound construction including a few single-atom 
fragments. Atom-based approaches have the advantages that fine-grained molecule sculpting 
can  be  performed  and  –  though  only  theoretically  –  the  complete  universe  of  chemical 
structures can be constructed. These advantages come at a price: the huge number of potential 
solutions complicates a systematic search for actually useful, chemically stable and druglike 
compounds.  The  strictly  atom-based  approach  is  prone  to  produce  a  large  fraction  of 
chemically  instable  and  unreasonable  compounds.  Fragment-based  approaches  offer  a 
shortcut to generating new ligands in a more meaningful way and significantly reduce the size 
of  the  search  space.  If  fragments  commonly  occurring  in  drugs  are  used  for  molecule 
assembly the designed compounds have a high chance of being druglike themselves.
52,53 In 
addition, the fragment-based approach improves the chance to produce chemically stable and 
synthetically feasible compounds. The reason is that fragment-based construction uses larger 
building blocks, which reduces the number of connection steps needed to assemble a new 
compound. It should be pointed out that all bonds formed by the software are artificial and 
therefore the chemical stability and accessibility of the virtual product cannot be guaranteed. 
The main advantage of fragment-based assembly over atom-based approaches is that many 
bonds of the designed structures are already predefined in a meaningful way by the fragments. 
It can be argued that this might be the major reason why the last purely atom-based de novo 
design program RASSE
94 was published over a decade ago. Nevertheless, using molecular 
fragments instead of atoms as building blocks alone does not guarantee to construct virtual 
compounds actually amenable to synthesis (this major objective of de novo design will be 
covered in more detail later).  
Several techniques have been developed for automated assembly of molecules. Alignment-
based  methods  like  BREED
59  and  the  fragment  shuffling  approach
75  first  align  different 
ligands bound to the same protein (or a homologue protein with high sequence similarity) by 
a backbone overlay of 3D protein structures. Strategic bonds from different ligands brought to 
close proximity are detected, broken and the four resulting fragments are swapped to yield 
two new compounds representing hybrids of original ligands (Figure 2). 
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Figure  2. O r i g i n a l  l i g a n d s  A  and  B  (top)  are  aligned  in  a  first  step 
(center). BREED
59 searches for strategic bonds (highlighted in red) and 
swaps fragments (A1, A2, B1 and B2) at this position in order to get 
hybrid structures (bottom) of original ligands. 
 
 
Other  approaches  for  structure  assembly  rely  on  molecular  force  fields  and  docking 
techniques. The basic idea is to independently place molecular fragments inside a binding 
cavity and connect them in successive steps. The software CONCERTS
36 is an early example 
of  using  molecular  dynamics  simulations  for  fragment  placing.  Fragments  are  moved 
according  to  a  molecular  force  field  to  obtain  low-energy  orientations  with  respect  to 
interactions with the binding site but without witnessing each other. Bonds can be formed 
between fragments that are brought to close proximity, but can also be broken in later steps. 
The constant rearrangement of bonds between fragments is supposed to result in compounds 
exhibiting interaction energies that are favorable to those of the unconnected fragments. Other 
de novo design programs employ docking tools in order to initially place fragments into a 
binding site. In general, two different strategies exist for this approach: growing and linking. 
Growing  approaches
8,17,19-22,25,33-35,64,94  start  with  one  fragment  that  already  satisfies  key 
interactions with the receptor and add more fragments step by step in order to improve the 
affinity  of  the  constructed  compound,  guided  by  the  scoring  function  of  the  underlying 
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docking program (Figure 3A). The linking strategy
10-14,15,67,79 first places several fragments at 
distinct parts of the pocket, which are then connected by linker fragments (Figure 3B). 
 
 
 
Figure 3. The growing strategy starts with a single building block and sequentially extends 
it  by  adding  new  fragments  (A).  The  linking  approach  first  saturates  key  ‘interaction 
hotspots’ of the cavity with building blocks and subsequently links them by special linker 
fragments (B). 
 
 
Examples for assembly techniques mentioned so far incorporate knowledge about the receptor 
structure. In a recent publication Kutchukian et al. describe an algorithm for ligand design 
that is independent of receptor information.
72 Their ligand-based de novo design tool uses 
connection  statistics  to  assemble  new  compounds.  The  algorithm  extracts  connection 
frequencies of predefined molecular fragments from a training set of reference compounds. 
These counts are then converted to probabilities termed transition probabilities forming the 
basis of a growth strategy implemented as a Markov chain of first order. Following the idea of 
a Markov chain,
95 the process of growing a molecule can be seen as a walk on a graph, where 
each  fragment  is  represented  by  a  node.  Edges  between  nodes  are  labeled  with  obtained 
transition probabilities. These labels represent probabilities to pass between nodes connected 
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by the edge. To grow a molecule, the algorithm starts with a randomly selected or given 
fragment (a node) and walks across the graph according to transition probabilities. Each time 
a node is visited the according fragment is added to the molecule (Figure 4). Since each node 
represents exactly one fragment, transition probabilities only depend on the fragment to be 
extended in the next step (first order property of the Markov chain). The process stops when 
all  potential  growth  sites  are  saturated,  a  user-defined  number  of  fragments  or  a  given 
molecular  mass  is  exceeded.  The  Markov  chain  is  supposed  to  generate  molecules  that 
reproduce connection statistics of the training set, therefore exhibiting increased probability to 
show desired molecular properties. 
 
 
 
Figure 4. A Markov chain model for compound assembly. A Markov chain
95 represents a sequential graph 
traversal: Every time a node is visited (indicated by a dashed line) the corresponding building block is added to 
the growing molecule (bottom). Edge labels (weights) correspond to the probability to walk along an edge in 
order to get to the next node. Weights are determined by connection statistics of fragments observed in a training 
set  of  molecules. P l e a s e  n o t e  t h a t  t h i s  g r aph  represents  a  simplification.  Typically,  weights w i l l  n o t  b e  
symmetric. 
 
 
Retrosynthesis rules form the basis of another category of ligand assembly strategies. Such 
rules define a set of substructures, each one built around a central bond that is deemed to be 
cleavable. Collections of compounds can be disassembled at these strategic positions to yield 
a set of molecular fragments. The same rules find application during the assembly process to 
construct new molecules by recombining the fragments. The most prominent representative of 
retrosynthetic  rules  is  the  Retrosynthetic  Combinatorial  Analysis  Procedure  (RECAP)
96. 
RECAP derives eleven cleavable bond types from common chemical reactions and defines 
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them by their structural environment (Figure 5). Examples of programs using the RECAP for 
mining  and  recombining  molecular  fragments  to  breed  new  druglike  compounds  are 
TOPAS
52,53 and its direct successor FLUX
62,63. Reconnection is restricted to attachment sides 
originating  from  the  same  disassembly  rule  in  order  to  enhance  the  probability  to  form 
chemically meaningful and stable bonds. 
The most sophisticated assembly technique in the sense of incorporating chemical knowledge 
is the simulation of established reaction protocols for fragment connection. Reaction-based 
approaches  use  formalized  reaction  schemes  to  mirror  the  bond  rearrangements  of  real 
synthesis steps in order to connect molecular building blocks. Established data formats for 
formalization of chemical reactions are the SMIRKS language
97 and the rxn file format
98. In 
case the building blocks are readily available (e.g. purchasable from a commercial vendor) 
this strategy not only enhances the chance to produce chemically reasonable compounds but 
also delivers direct blueprints for possible synthesis routes. The software SYNOPSIS
57 is such 
an example. 
 
 
Figure 5. Eleven cleavable bond types defined by RECAP
96. 
 
 
1.1.3 Search Strategies 
De novo design is faced with an almost infinite search space of small organic molecules. An 
attempt to assess the actual size of this space resulted in an estimate of 10
60 compounds.
99 
This figure might slightly overestimate the real size of the space relevant for drug discovery 
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because  it  does  not  account  for  chemical  stability  and  druglikeness.  Nevertheless,  it  still 
prohibits approaches that try to enumerate all possible structures. For this reason, de novo 
design programs have to truncate the number of molecules they consider during a design run. 
Most of the programs apply stochastic optimization techniques to cope with such large search 
spaces.
4 In order to understand how these algorithms work it helps to imagine the chemical 
space as a wavy surface. Each point on the surface represents a molecule. Similarity (to 
whatever quality) between molecules is expressed by distance in this space, so that similar 
molecules are close to each other. The quality of a compound (score, biological activity) is 
expressed by the height of the respective search point where better quality is expressed by a 
higher level. The basic idea of stochastic search algorithms is to explore the neighborhood of 
the current search point by sampling a few surrounding search points in close proximity (also 
termed ‘local search’). Information gained by this process is used to extrapolate about the 
actual structure of this subspace and move along the most promising direction. Successful 
application of local search strategies requires a ‘smooth’ response characteristic, i.e. small 
structural changes (movement in the space) result in small changes of the score, while large 
steps  cause  large  differences  of  scores.
100  Although  it  has  been  shown  that  this  is  not 
generally the case in arbitrary chemical spaces and associated activity landscapes,
101,102 search 
algorithms relying on local optimization have proven to deliver results of practical relevance 
and sufficient quality for many complicated optimization problems including molecular de 
novo design.
103,104 However, appliance of stochastic optimization does not come without a 
drawback: Many optimization algorithms employ heuristics, i.e. they cannot guarantee to find 
the absolute optimal solution for a given problem. Their stochastic component renders it most 
likely that two runs of same algorithm applied to the same problem deliver different results. 
Typically, multiple runs of heuristic approaches have to be performed to yield statistically 
sound  results  of  retrospective  evaluations  and  enhance  the  probability  to  attain  useful 
outcome in prospective studies. The reason for this is that even if the underlying scoring 
function responds smoothly to movements in the search space, local optima can still occur 
and trap local search strategies. A local optimum is a point in the search space that is assigned 
with a better score than all points in a certain neighborhood around it, while the search space 
still might offer better search points in regions beyond this neighborhood. The reliance on the 
local behavior around the current search point can trap a search algorithm. Although search 
techniques that support the ability to escape local optima have been developed (vide infra), 
there is still no guarantee to find the global optimum. Different results of optimization runs on 	
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the  same  problem  originate  from  the  fact  that  the  algorithm  converges  on  different  local 
optima due to its stochastic component.  
Markov chains (vide supra) represent an example of a stochastic search strategy.
72,95 Their 
random sampling procedure is often coupled to a Metropolis criterion in order to facilitate 
escaping from local optima.
18,105,106 According to the Metropolis criterion, structural changes 
improving the score of a molecule are accepted in any case, whereas steps degrading the score 
might be rejected: the more a modification degrades the score, the higher the probability to 
reject it. According to the Metropolis criterion the probability to accept search point j coming 
from i is 
 
€ 
Pi→ j = min(1,e
−( f (i)− f ( j))/T),                (4) 
 
where f(i) denotes the quality of search point i (better solutions receive higher values) and T is 
a constant scaling factor. 
Simulated annealing techniques pick up this idea but dynamically change the calculation of 
rejection probabilities for a degrading step.
57,107 At the beginning of an optimization run, 
degrading  modifications  have  a  higher  chance  to  be  accepted  in  order  to  prevent  early 
convergence on a (most likely globally unfavorable) local optimum. In later steps, when the 
search space has already been explored more intensively and found optima are more likely to 
be  of  practical  interest,  the  dynamic  calculation  of  acceptance  probabilities  will  tune  the 
algorithm to preferably stay in the current search region. This is achieved by a more rigorous 
calculation  of  rejection  probabilities  for  score-degrading  movements  in  the  search  space. 
Computationally, simulated annealing is realized by constantly reducing the scaling factor T 
of equation (4) during the optimization. 
Several  stochastic  search  algorithms  have  been  derived  from  optimization  strategies 
observable in nature, of which evolutionary algorithms (EA) and particle swarm optimization 
(PSO) are prominent examples.
108 EA is an umbrella term for several optimization techniques 
inspired  by  the  idea  of  biological  evolution.  A  population  of  search  agents  (representing 
molecules in the context of de novo design) is iteratively exposed to random variation and 
selection. Variation is introduced by genetic operators like mutation and genetic crossover. 
Selection is performed according to the score of individuals assigned by a scoring function 
(also termed fitness function in this context). Better search agents are more likely to survive 
and continue to influence the search process, while less fit individuals die out. Evolutionary 
algorithms mainly differ in the way they encode individuals and how selection and variation 	
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are implemented. Examples of de novo design software applying evolutionary algorithms are 
FLUX
62,63 and LigBuilder
51. PSO algorithms mimic the behavior of real swarms of animals 
searching, e.g., for food resources.
109 A set of virtual search agents (termed particles) moves 
in the search space. A position in the  search space equals a solution to the optimization 
problem.  The  direction  of  movement  is  influenced  by  communication  and  information 
exchange  between  particles  about  their  individual  search  success.  Communication  is 
implemented as a social memory, which is accessible by every particle. The social memory 
stores the best search point found so far by the swarm as a collective. In addition, each 
particle also stores the best search point it has explored so far in its personal memory. Search 
points stored in the social and personal memory attract the particles during their search. As 
the search proceeds, promising regions will be explored thoroughly by many particles, while 
areas found to be less attractive are widely ignored. PSO has been introduced to the field of 
de novo drug design by the program COLIBREE.
68  
 
Stochastic optimization is not the only way software tools for molecular de novo design try to 
manage the large search space they are confronted with. There are examples of programs 
applying  deterministic  search  algorithms:  FlexNovo
64  uses  a  grow  strategy  to  connect 
molecular  fragments.  In  a  preprocessing  step,  each  fragment  is  docked  into  the  receptor 
binding site to obtain a single score which serves as a filtering criterion during the design 
process. Prior to the extension of the growing molecule by adding the next fragment, an 
estimation of the maximal score achievable by the extended molecule and a set of additional 
filters are applied to limit the number of potential fragments. Only fragments that have a good 
chance to improve the score of the molecule are considered. In addition, only the best k 
molecules  emerging  from  an  extension  cycle  are  considered  in  subsequent  steps.  Thus, 
FlexNovo employs a ‘greedy’ strategy
110 and a set of filtering criteria to reduce the search 
space to promising sub-regions. 
A further strategy to cope with large numbers of potential search points is to employ scoring 
functions designed to feature fragment additivity, i.e. the score of a complete molecule is 
computed as the sum of scores its fragments. This offers the advantage to avoid scoring every 
possible fragment combination. Instead, each entry of fragment library can be scored alone, 
and  optimal  combinations  of  fragments  can  be  computed  without  the  need  to  explicitly 
assemble them. To illustrate the advantage of additive scoring schemes let us consider two 
fragment libraries, each containing 1,000 entries. A possible product is a combination of two 
fragments, one fragment from each library. Full enumeration of all possible products would 	
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result in 1,000,000 molecules (1,000
2) and the same number of score calculations. An additive 
scoring function would only have to score each fragment once, which means that only 2000 
(1000 + 1000) score calculations would be required. This simple example demonstrates that 
the  search  space  grows  exponentially  with  the  number  of  fragments.  One  can  expect  the 
advantage of additive scoring schemes regarding computational cost to be more serious in 
practically relevant de novo design scenarios. Two examples of software tools that make use 
of additive scoring schemes are BI CLAIM
77 and a computer program proposed by Nikitin et 
al.
60. However, regardless of the advantages, it must be stated that additivity of ligand scores 
is a feature that is artificially introduced as it represents a simplifying assumption of the 
scoring scheme. Binding energies of ligand–receptor interactions cannot be expected to be 
additive in general.
111 
1.1.4 Multi-objective Optimization and Feasibility by Chemical Synthesis 
The primary task of de novo design is to propose novel compounds with a desired biological 
effect, i.e. affinity to a target macromolecule. Although scoring functions considerably differ 
in their approach to estimate biological activity, every de novo design algorithm takes this 
objective into account. For this reason it can be referred to as the primary constraint of de 
novo design. However, biological activity is not the only requirement for a compound to be a 
promising candidate for further investigation. Druglikeness, pharmacokinetic properties like 
absorption,  distribution,  metabolism  and  excretion  (ADME),  toxicity,  off-target  activity 
(selectivity),  and  accessibility  by  chemical  synthesis  are  examples  of  secondary  target 
constraints.
4 Such objectives can either be directly addressed by an explicit scoring term or 
implicitly  accounted  for  by  the  design  strategy.  For  example,  a  fragment-based  design 
approach based on fragments derived from known drugs implicitly considers druglikeness. In 
case  additional  scoring  terms  explicitly  consider  secondary  constraints,  de  novo  design 
becomes  a  multi-objective  optimization  task.  One  possibility  to  make  multi-objective 
optimization  compatible  to  one-dimensional  optimization  techniques  is  to  calculate  a 
combined score as a weighted sum of single scoring terms. This requires careful weighting of 
the different design objectives and is prone to lead to unfavorable results, especially in the 
case of conflicting design objectives.
4 The reason is that in this case ‘average’ structures 
fulfilling  all  objectives  on  a  comparable  but  overall  weak  level  are  likely  to  emerge.  In 
contrast, Pareto optimization
112 delivers a collection of results that contains solutions focusing 
on different subsets of objectives (the so-called ‘Pareto front’). The Pareto front is formed by 
non-dominated  solutions:  a  solution  is  dominated  if  there  is  at  least  one  solution  in  the 
population featuring a better score in every optimization objective (Figure 6). Non-dominated 	
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solutions therefore represent trade-offs between competing constraints. Pareto optimization 
does not need any weighting of objectives prior to scoring. It provides the user with a list of 
candidate  solutions  for  every  objective,  leaving  the  decision  to  the  user  which  of  the 
objectives should be emphasized. Pareto-optimization has been introduced to de novo drug 
design in 2004 by Brown and coworkers.
113 Two years before, the program MoSELECT
112 
implemented Pareto optimization for the design of combinatorial libraries. 
Secondary constraints do not necessarily have to be employed during the design process. 
Another way is to use them as filtering criteria after the actual design run to narrow down the 
number of structures of potential interest (‘post-generation’ scoring).
114,115 
 
 
 
Figure 6. A set of solutions (grey circles) for a two-dimensional optimization 
problem.  The  figure  next  to  each  circle d e n o t e s  t h e  n u m b e r  o f  d o m i n a t i n g  
solutions.  For  one  solution,  exemplary  determination  of  the  number  of 
dominating solutions is presented (dotted lines). Three solutions are dominating, 
since they are better in all objectives. Non-dominated solutions form the Pareto 
front (dashed line; figure adapted from reference 4). 
 
 
Among the aforementioned secondary design constraints, synthetic feasibility of proposed 
structures is of crucial importance for molecular de novo design.
81,114 The actual synthesis of 
designed compounds is key to both practical evaluation of the software as well as drug design 
projects.  The  assembly  process  represents  the  part  where  synthetic  feasibility  can  be 
incorporated directly during the design. Over the years of development in the field, steadily 
increasing effort has been put on this issue: from atom-based molecule build-up to rule-based 
assembly of fragments and, finally, virtual synthesis by established reaction protocols and 
available building blocks. Among all strategies mentioned only the latter approach is able to 
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additionally  propose  synthesis  routes  for  each  designed  compound,  which  can  be  an 
advantage of practical value. 
Instead of implicitly accounting for chemical feasibility by an advanced assembly method, 
another  strategy  is  to  use  a  suitable  scoring  function  (thereby  making  synthesizability  an 
explicit  design  objective).  For  example,  the  software  SYLVIA
116  can  be  used  to  score 
designed molecules by their chemical feasibility after they have been assembled. However, 
this approach does not suggest synthesis routes. Additional software especially designed for 
this purpose can be employed for synthesis planning. For example the computer programs 
CAESA
117  or  Route  Designer
118  can  be  applied  to  suggest  synthesis  plans  for  designed 
compounds post-hoc. 
 
1.2 Examples of De Novo Design Software Tools 
1.2.1 LUDI 
The program LUDI
10-14 is an example of a software solution from the early days of computer-
assisted  de  novo  design.  Despite  being  a  pioneer  in  the  field,  LUDI  still  represents  a 
sophisticated  approach  to  receptor-based  design  and  can  be  deemed  one  of  the  most 
successful de novo design tools.
119 The first step of a LUDI construction run comprises the 
placement of molecular fragments within the receptor binding cavity. The fragment library 
can be defined by the user. Fragments are placed so that they satisfy potential interaction 
centers  within  the  protein  pocket.  The  algorithm  accounts  for  directed  characteristics  of 
interactions (in particular hydrogen bonds) by a vector representation of interaction centers 
and complementary interaction sites of the fragments. Fragment positions are optimized by 
minimizing deviations from optimal orientations of interaction partners. Steric clashes with 
the protein are penalized. A second, empirical scoring function is employed in a subsequent 
step in order to rank all fragment poses. The most promising fragments placed within the 
binding site are then connected using linker fragments (linking approach) to yield complete 
ligand candidate structures. For example, LUDI has been used to design inhibitors of the 
human immunodeficiency virus reverse transcriptase (HIV-RT).
120 The scaffold identified by 
the software was slightly modified to simplify the synthesis. A series of structural variations 
and sidechain replacements resulted in a set of new structures inhibiting different enzymatic 
activities of HIV-RT (Scheme 1). 
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Scheme 1. LUDI
10-14 has been successfully applied to design an inhibitor of the HIV-RT. Starting with the 
structure of the binding site, LUDI first placed fragments into sub-regions of the pocket and linked them by a 
phenyl moiety in a second step. The resulting structure was finally decorated with an amide sidechain by LUDI. 
Subsequent  manual  optimization  exchanged  the  pyrrole  ring  with  an  imidazole  to  simplify  the  chemical 
synthesis.  A  series  of  compounds  based  on  this  scaffold  has  been  synthesized  and  led  to  different  active 
molecules for several enzymatic activities of the target (the given IC50 has been determined with respect to DNA 
polymerase activity of HIV-RT). 
 
1.2.2 Skelgen 
In the late 1990s, Todorov and Dean proposed two algorithms for computer-assisted molecule 
construction forming the backbone of the Skelgen software.
39,40 Skelgen features a two-step 
process to generate new ligand candidates. The approach is similar to the idea of SPROUT
19-
22,  which  was  published  five  years  earlier  in  1993.  While  the  first  step  constructs  bare 
molecular skeletons, the second step implements an atom type assignment in order to turn 
skeletons  into  complete  virtual  molecules.  Molecular  skeletons  are  constructed  by  the 
stochastic assembly of so called template fragments. For this purpose, Skelgen has access to a 
library of special fragments manually grouped into different template sets by the user. A 
template  only  consists  of  carbon  and  hydrogen  atoms.  After  an  initial  skeleton  has  been 
generated,  it  is  optimized  to  sterically  fit  the  binding  cavity  of  the  receptor.  During  this 
process, the skeleton can be rotated and translated as a whole, and single bonds are rotated to 
sample  the  conformational  space  of  the  skeleton.  In  addition,  fragments  may  be  added, 
removed or exchanged. In the latter case, fragments are only replaced by other fragments 
belonging to the same template set. The whole optimization procedure is implemented as a 
simulated annealing process. Scores of skeletons are assessed by a scoring function that takes 
both  intermolecular  and  intramolecular  steric  interactions  into  account  as  well  as  torsion 
energies. After the skeleton has been sterically optimized to fit the receptor binding site, 
element types are assigned to skeleton vertices in the second step. The aim is to maximize the 
complementarity  of  the  emerging  molecule  to  the  pocket  in  terms  of  electrostatic  and 
hydrogen bonding interactions. For this purpose an empirical scoring function is used. A 
branch-and-bound algorithm in combination with a depth-first search is employed to exclude 
unfavorable  element  type  assignments  and  efficiently  find  good  solutions  for  this 
combinatorial problem. Although originally implemented as a receptor-based method, a later 
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version  of  Skelgen  also  features  a  ligand-based  design  mode  based  on  three-dimensional 
steric and pharmacophoric constraints derived from a reference ligand.
42 
In  a  large  study  Firth-Clark  and  coworkers  employed  Skelgen  to  generate  new  ligand 
candidates for the human estrogen receptor (ER) α.
121 Skelgen generated a total of 5,492 
unique  designs  based  on  seven  different  crystal  structures  of  the  target  protein.  For  each 
receptor structure the 50 top scoring molecules were selected for a subsequent clustering 
analysis. These 350 compounds could be clustered into 22 distinct sets based on common 
substructures. Out of 17 compounds picked for synthesis and testing (selection was performed 
to cover a broad range of clusters), five (30%) showed >40% inhibition at a concentration of 
10 µM. Five compounds (of which four are structurally novel) have an IC50 ≤25 µM. The 
most potent compound exhibits an IC50 of 340 nM (Scheme 2). 
 
 
 
Scheme 2. The two most potent inhibitors designed by the Skelgen software
39-44 for human estrogen receptor α. 
 
1.2.3 TOPAS/FLUX 
TOPAS
52,53 and its successor FLUX
62,63 are examples of a purely ligand-based de novo design 
paradigm. Designed molecules are evaluated by their similarity to a reference compound. For 
this purpose, the relative topological distributions of potential pharmacophore points on the 
two-dimensional molecule structure are calculated (CATS descriptor
122). Molecular fragments 
for construction are derived from the disassembly of known bioactive compounds by applying 
the RECAP
96 rules retrosynthetically. The same rules also guide the forward design process: 
during construction, only fragment attachment sites derived from the same cleavage rule can 
be reconnected (i.e. a carbonyl and a nitrogen attachment site are only allowed to form an 
amide bond if both have been part of an amide bond prior to disassembly). An evolutionary 
algorithm  directs  the  search  process:  a  strict  selection  criterion  allows  only  the  fittest 
compound of a ‘population’ to survive and produce offspring by random fragment exchange 
(mutation  operator).  In  contrast  to  TOPAS,  FLUX  also  features  a  crossover  operator 
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recombining parts of ‘parent’ structures to generate new fragment combination in the next 
generation.  Starting  with  a  randomly  assembled  compound,  the  optimization  process  is 
supposed to breed structures with increasing fitness over time. 
An example for successful ligand-based de novo design has been published by researchers at 
Roche  in  2000.
53  TOPAS  suggested  structures  supposed  to  block  the  human  K+-channel 
Kv1.5. The top-scored molecule 1 was synthesized and showed the desired effect on the target 
(Scheme 3). Minor modification led to compound 2, which is equal to the reference ligand 
with respect to potency. 
 
 
Scheme 3. Compound 1 designed by TOPAS and its close structural analog 2 were synthesized and block the 
human K+-channel Kv1.5. 
 
1.2.4 BOMB 
The software BOMB
65 features free energy perturbation (FEP) as a post-run scoring scheme 
to compute relative binding energies for the most promising designs. FEP makes use of the 
thermodynamic cycle in order to estimate differences of binding energies between (preferably 
close) structural analogs (relative binding energies). For this purpose, one ligand has to be 
‘morphed’ into another by incremental small steps of structural changes. Each intermediate 
step needs to be evaluated in terms of binding energies to the receptor pocket. This time-
consuming and computationally demanding process is one of the most sophisticated methods 
available to estimate relative differences in binding energies taking solvatation effects into 
account. Since the morphing process works best on structurally similar compounds, BOMB 
generates series of ligands by decorating a fixed core fragment with various sidechains. The 
selection of the core fragment and its placement within the binding site is accordingly the first 
step of a design run. Several layers of fragments from a fixed set of building blocks that are 
clustered  into  multiple  groups  can  be  added  to  grow  the  seed  structure  to  final  ligand 
candidates. Each grown molecule is geometrically optimized within the pocket by a force 
field minimization and evaluated according to a QSAR-like scoring function that was trained 
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to reproduce experimentally determined activity values. Finally, FEP is employed to re-score 
and rank the most promising compounds after a design run. 
BOMB has been successfully employed in a de novo design study to identify a series of new 
inhibitors of HIV-RT.
65 An example of a designed compound from this study is presented in 
Scheme 4. 
 
 
 
Scheme 4. Example of a potent inhibitor of HIV-RT designed with 
the help of BOMB
65 based on a fixed core structure. 
 
 
Similar to BOMB, a few de novo design programs start off with a user-defined fragment. 
Although this breaks with the concept of ‘pure’ de novo design to invent new molecules from 
scratch, it is a worthwhile strategy to incorporate knowledge about privileged fragments into 
the  design  process.  Depending  on  the  focus  of  the  software,  the  seed  fragment  can  be 
anything from molecular scaffold (e.g. BOMB, COLIBREE
68) to a set of sidechains (e.g. 
Recore
123). 
 
1.3 Outline 
This work presents a new approach to computer-assisted de novo design of ligand candidate 
structures. Special focus was put on the practical evaluation of the software. Only a small 
number of de novo design programs have been tested for their ability to propose synthetically 
feasible compounds by practical synthesi. This represents a problem computer-aided de novo 
design suffers from since the beginnings of the research field. The main reason might be the 
extensive costs and effort associated with chemical synthesis of candidate molecules. The 
decision to synthesize a compound depends on the estimated tradeoff between the ease of 
synthesis and its presumed chance to exhibit the desired biological activity. Enhancing the 
ease of synthesis of candidate molecules therefore raises the probability that some compounds 
will actually be selected for synthesis and practical testing. For this reason, the proposed 
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software DOGS (Design of Genuine Structures) was developed to maximize the chance of 
designed structures to be synthesizable with little effort. In fact, DOGS not only suggests new 
compounds but also provides the user with at least one possible synthesis pathway for each 
compound. DOGS features an assembly process based on available molecular building blocks 
and a set of established reaction schemes, which forces the software to follow up construction 
pathways representing direct blueprints for possible synthesis routes. Only a small number 
existing software tools (e.g. SYNOPSIS
57 and BI CLAIM
77) provide the user with synthesis 
routes for designed compounds. 
Despite the suggestion of synthesis pathways, the reaction-driven construction of candidate 
molecules can be exploit in an additional way: Restrictions dictated by chemical reactions 
limit the number of constructible molecules in a well-motivated way. This can be exploited by 
the applied search algorithm, as the size of the search space is significantly narrowed down 
compared to an unconstraint combination of fragments. DOGS features a deterministic search 
algorithm implemented as a greedy strategy. Molecules are grown in a stepwise process, in 
which for each extension cycle not more than the best k of all generated molecules will be 
followed up in the next round.  
Quality of designed products is assessed using a ligand-based scoring scheme. Similarity to 
the reference ligand is computed by a graph kernel method especially suited for the stepwise 
growing  process.  Two  graph  representations  of  molecules  (molecular  graph  and  reduced 
graph)  have  been  implemented  to  allow  for  different  levels  of  abstraction  from  the  two-
dimensional molecular structure. 
Theoretical  evaluation  of  the  software  with  respect  to  general  properties  of  designed 
compounds was performed as well as analyses of generated scaffolds. Finally, DOGS was 
tested for its ability to contribute to a realistic drug design project in two practical case studies 
on ligand design for human γ-secretase and human histamine H4-receptor. 	
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2 Material and Methods 
	
 ﾠ
2.1 Library of Chemical Reactions 
The way the DOGS algorithm builds up new candidate structures mimics a stepwise synthesis 
pathway as applied in a laboratory. This strategy is supposed to deliver a direct blueprint for 
the actual synthesis of proposed candidate structures. For this approach, established reaction 
protocols  need  to  be  formalized  in  order  to  make  them  processable  by  a  computer.  The 
reactions applied within DOGS were encoded using the formal language Reaction-MQL
124. 
Reaction-MQL  is  a  line  notation  language  that  can  be  used  to  describe  functional 
transformations of molecules. The specification of a reaction as a Reaction-MQL expression 
consists of an educt side on the left and a product side on the right. Educts are specified only 
by substructures that are directly involved or essential for the reaction (reaction center) in 
order to make the description applicable to wide spectrum of educts with variable substituent 
groups (R-groups). The product is described as bond rearrangements caused by the reaction 
(Scheme 5). All Reaction-MQL representations used here feature educts with variable R-
groups in order to make them as generic as possible and broaden the spectrum of possible 
products. 
 
 
C-C1[!ring](=O7)-C4[!aromatic  &  bound(-H)]-C5[!aromatic  &  bound(-H)]-C2(=O6)-C  ++ 
C[!bound(=O)]-N3[allHydrogens=2  &  charge=0]  >>  Paal-Knorr  pyrrole  >>  C1$1-N3-C2=C5-
C4$=1 
 
 
Scheme 5. Example of a Paal-Knorr pyrrole reaction encoded as Reaction-MQL expression (top). 
Educt substructure descriptions (left part) are separated by ‘++’. Educt side and product side (right 
part) are separated by ‘>> ID >>’ where ID is an arbitrary identifier for the reaction. A direct 
structural representation of the line notation description including atom identifiers is shown in the 
middle. The conventional structural representation of the reaction (bottom) denotes variable parts 
of molecules by R-groups (R
x). 
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Catalysts or invariant educts are not denominated in the reaction string. For example, the 
reaction expression presented in Scheme 6 does not explicitly list sodium azide as an educt 
because it will not introduce variable sidechains on the product side. Invariant educts are 
implicitly  included  on  the  product  side  by  adding  relevant  atoms.  Only  educts  explicitly 
mentioned in a Reaction-MQL expression are considered as reaction components in DOGS. 
This means that the reaction of Scheme 6 is referred to as a one-component reaction in this 
work, although its real-life counterpart involves more than one educt. 
 
C-C1#N2 >> Tetrazole  >> C1$1=N2-N[charge=-1]-N=N$-1 
 
 
 
Scheme 6. Reaction-MQL representations (top) only list educts 
with  variable  sidechains.  Atoms  from  invariant  educts  are 
automatically  added  when  processing  the  reaction.  For  this 
reason the sodium azide is not explicitly present in the reaction 
expression, although it is part of the reaction (bottom). 
 
 
A  set  of  established  reaction  protocols  was  collected  from  the  literature  and  encoded  as 
Reaction-MQL  expressions.  Special  focus  was  drawn  on  ring  closure  reactions  forming 
substructures  of  pharmacological  interest.  Other  selection  criteria  comprised  high  product 
yields,  simple  application,  broad  diversity  with  respect  to  educt  R-groups  and  minimal 
exertion of toxic catalysts. Although preferred, a reaction did not necessarily have to fulfill all 
requirements to be considered. 
The  collected s e t  comprises  83  reactions,  of  which  58  are  unique  and  25 a r e  charge  or 
symmetry  variations  (a  complete  list  can  be  found  in  section  Coupling  Reactions  in  the 
supplement).  Out  of  the  58  unique  reactions  34  describe  ring  formations.  A  reaction i s  
classified as a ring closing reaction if the product contains a cyclic substructure that is not 
present in one of the educts. All reactions require one or two educts (one- and two-component 
reactions) and result in a single product (A  B or A+BC). The fact that each specification 
only describes one product guarantees a one-to-one assignment of a reaction and a product. 
While this simplifies the application of virtual reactions during the design process it raises a 
problem when a reaction involves a symmetric educt substructure and is not characterized to 
be  regioselective.  In  this  case,  the  reaction  is  described  by  two  distinct  Reaction-MQL 
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specifications, each forming one regioisomer. An example of such a reaction is presented in 
Scheme 7. 
 
C1-C2[!ring](=O10)-C3[allHydrogens=2]-C4(=O11)-C5 >> 3-nitrile pyridine (symmetry 1)  >> 
N$1=C(-O)-C(-C#N)=C2(-C1)-C3=C4$-1(-C5) 
 
 
 
 
C1-C2[!ring](=O10)-C3[allHydrogens=2]-C4(=O11)-C5 >> 3-nitrile pyridine (symmetry 2)  >> 
N$1=C(-O)-C(-C#N)=C2(-C5)-C3=C4$-1(-C1) 
 
 
 
Scheme  7. E x a m p l e  o f  a  reaction  forming r e g i o i s o m e r  p r o d u c t s  d u e  t o  a  s y m m e t r i c  e d u c t  
substructure. The reaction is split in two separate reaction expressions in DOGS. Corresponding 
Reaction-MQL expressions are presented above each reaction scheme. 
 
 
2.2 Library of Synthesis Building Blocks 
DOGS uses commercially available synthesis building blocks for the construction of new 
molecules.  A  subset  of  the  Sigma-Aldrich
125  catalog  containing  about  56,878  chemical 
building blocks was downloaded as SDF file from the ZINC database.
126,127 These compounds 
served as a basis to extract the final set of building blocks available to automated design by a 
three-step preparation protocol.   
 
1) In the first step, building blocks were standardized and unsuitable entries wer filtered out. 
For  this  purpose,  a  preprocessing  routine w a s  d eveloped  and  implemented  in  the 
programming  language S V L  using  the  software  MOE
128  (version  2009.10).  This  routine 
comprises multiple filtering criteria: 
 
•  Compounds with a molecular mass of less than 30 Da or more than 300 Da were 
removed. 
•  Compounds having more than 4 rings were removed. 
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•  Compounds exhibiting any element type other than C, N, O, S, P, F, Cl, Br, I, B, Si 
and Se were removed. 
•  Compounds containing more than three fluoride atoms were removed. 
•  Compounds exhibiting atoms with incorrect valences were removed. 
•  Compounds exhibiting unwanted substructures (Scheme 8) were removed. 
•  Protonation states and formal charges were set according to MOE’s washing routine 
(e.g. carboxylic acids were deprotonated, most primary, secondary and tertiary amines 
were protonated). 
•  Duplicate entries were removed. 
 
Definitions  of  unwanted  substructures  (Scheme  8)  were  compiled  on  the  basis  of  rules 
published by Hann and coworkers.
129 
 
 
 
Scheme 8: Unwanted substructures according to Hann et al.
129 Building blocks containing one of 
these substructures are removed from the stock of building blocks for DOGS. (Ar: aromatic) 
 
 
2)  In  the  second  step, t he  filtered  compound  set  was  processed  by  a  collection  of 
preprocessing reactions. A set of 15 functional group addition (FGA) and functional group 
interconversion (FGI) reactions was compiled from the literature and encoded as Reaction-
MQL expressions (for a complete list of preprocessing reactions see section Preprocessing 
Reactions  in  the  supplement).  FGA/FGI  reactions  are  supposed  to  introduce  reactive 
functional groups to building blocks in order to make them applicable to coupling reactions in 
the design process. Every time a building block was converted by any of the 15 reactions, the 
original version was kept and the converted building block added to the library. 
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3) The final step of the preparation process comprises the annotation of reactive substructures 
present at each molecular fragment. Structural information and substructure annotations were 
then stored in a MySQL
130 database. For annotation, every building block was checked for the 
presence  of  any  reactive  substructure  defined  in  the  83  Reaction-MQL  expressions  of 
coupling  reactions.  A  bit  vector  storing  this  information  was  built  for  every  synthesis 
fragment. The bit vector holds a ‘1’ at a certain position if the respective substructure is 
present (i.e. the building block can serve as an educt for a certain reaction). Accordingly, the 
length of this bit vector is exactly the same as the number of reactive substructures defined by 
the coupling reactions. Storing this information together with each building block is supposed 
to speed up the selection of suitable reaction partners during the design process. In case a 
building block does not contain any of the defined reactive substructures (i.e., all bits have 
zero values) the building block is neglected and not stored in the database because it will not 
be able to act as reaction partner during molecule construction. 
Figure 7 summarizes the stepwise process of preparing the building block library. Starting 
with 56,878 synthesis fragments, the final library contains 25,144 entries. 
 
 
 
Figure 7. Preprocessing protocol setting up the DOGS building block library. Figures in parentheses give the 
number of building blocks involved at the respective stage. 
 
 
2.3 Design Algorithm 
 
DOGS  generates  new  molecules  by  iterating  through  the  design  cycle.  One  design  cycle 
comprises the modification of a current intermediate product by applying one of the chemical 
reactions from the library, i.e. the extension of the intermediate product. The product of one 
design  cycle  represents  an i n termediate  product,  which  is  modified  in  the  subsequent 
iteration. A design cycle has two steps: 
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1.  Selection of applied reaction 
An intermediate product Z will typically exhibit more than one functional group that 
can be addressed by reactions from the reaction library. Each of these groups can 
potentially serve as an attachment point (AP) to connect another building block. In 
order  to  identify  the  most  promising  AP  of  Z  and  the  reaction  to  apply,  DOGS 
introduces the concept of minimal dummy fragments. A minimal dummy fragment is a 
virtual molecule that exclusively features the minimal structural demands that must be 
fulfilled to participate in a certain reaction. The application of this concept is supposed 
to estimate the minimum structural changes a reaction will introduce (Figure 8). The 
definition  of  a  reaction  therefore  determines  corresponding  minimal  dummy 
fragments,  as  they  depend  on  the  way  a  reaction  defines  reactive  substructures 
involved. A one-component reaction does not define any minimal dummy fragment. It 
can directly be applied to a molecule without the involvement of a second reactant. 
Thus,  structural  changes  to  Z  do  not  need  to  be  estimated  but  are  determined  by 
simply  applying  the  reaction.  In  contrast, a  t w o -component  reaction  defines  two 
minimal dummy fragments. 
In order to extend Z, the algorithm first detects which of the implemented reactions 
can be applied to the attachment points offered by Z. Each of these reactions is applied 
to Z with a complementary minimal dummy fragment, leading to a list of dummy 
products.  Here,  one  dummy  product  corresponds  to  exactly  one  reaction.  By 
subsequently scoring the dummy products DOGS implicitly scores the corresponding 
reactions.  The  reaction  breeding  the  top  scoring  dummy  product  is  selected  to  be 
pursuit in the next step. In case more than one top scoring reaction is identified all of 
them are considered in step 2. 
2.  Selection of synthesis building block 
In  case  step  1  selected  a  one-component  reaction  it  is  directly  applied,  and  Z i s  
modified accordingly. Otherwise (two-component reaction), the reaction is performed 
using all building blocks from the library holding the respective reactive substructure 
(Figure 8). Every generated product is scored according to the scoring function. The 
top-scored compound is selected and represents the extended intermediate product for 
the next design cycle. In case more than one intermediate product scores favorable, all 
of  them  are  considered  for  the  next  round.  In  order  to  truncate  the  number  of 
molecules  generated  during  each  step  and  to  prevent  combinatorial  explosion,  the 	
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maximal number of intermediate products proceeding to the next extension round is 
limited to 10. 
 
 
 
Figure 8.	
 ﾠTwo-step procedure of an extension cycle. Step 1 selects the reaction by scoring generated dummy 
products. In the example, only two reactions can be applied (Suzuki coupling and amide coupling), and the 
amide dummy product scores favorable. In step 2, all educts from the building block library exhibiting a suitable 
amine are added to the growing molecule. The top-scoring product represents the extended intermediate product 
and is selected for the next design cycle. 
 
 
The building block a synthesis path starts with is selected among all entries of the library. For 
this purpose the algorithm evaluates every building block processed by the dummy reaction 
steps  according  to  the  scoring  function.  Each  of  the  n  top  scoring  building  blocks  are 
considered as a starting point for a distinct synthesis path. The value of n is defined by the 
user to control the number of compounds proposed during a design run. 
Once the design of a new compound based on a selected starting building block is initiated it 
will be continued until one of two stop criteria is fulfilled.  
The first stop criterion controls the molecular mass of designed compounds. The reference 
compound’s  mass  (100%)  defines  a  relative  lower  (70%)  and  upper  (130%)  bound.  A 
constructed molecule has to exhibit a molecular mass lying within these boundaries to be 
accepted  as  a  valid  final  product.  During  the  design  of  a  new  molecule  the  algorithm 
continuously adds building blocks until the resulting intermediate product exceeds the lower 
mass boundary. Up to this step the extension of the intermediate product is accepted even if 
the  score  degrades  from  intermediate  product  i  to  i+1.  Once  the  molecular  mass  of  an 
intermediate  product  lies  within  the  defined  range,  the  algorithm  will  only  accept  a 
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subsequent extension step if it results in an improvement of the score. In case the addition of a 
building block leads to a lower score or causes the molecular mass to exceed the upper weight 
constraint, the last reaction step is neglected and the previous intermediate product is added to 
the list of final products. 
The second stop criterion is supposed to truncate the number of synthesis steps in order to 
keep proposed synthesis pathways short. A pathway is interrupted regardless of any other 
condition when a certain number of synthesis steps (here: 4) is exceeded. In this case, the 
intermediate  product  formed  by  the  last  valid  reaction  step  is  added  to  the  list  of  final 
products and a new synthesis pathway is launched based on another starting building block. 
Figure 9 presents the core of the design algorithm. 
 
 
 
Figure 9. A: Flowchart of the DOGS design algorithm. The stop criterion for maximum number of reaction 
steps is not included. B: Detailed description of flowchart element B (grey circle). It comprises the key steps to 
modify intermediate product Z in order to yield Ž by applying in silico reactions. 
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DOGS tries to construct at least one compound starting from each of the n building blocks 
considered as most promising starting points. It is possible that an initiated synthesis path 
does not produce a final product. This is the case if the growing intermediate product does not 
offer an attachment point to add another building block before it exceeds the minimal mass 
limit. DOGS automatically skips this particular synthesis and increments n by 1 to guarantee 
that at least n final products are generated. Typically, a run will result in more than n final 
products because synthesis pathways can split if different top scoring intermediate products 
are generated. In this case, more than one final product will be designed on the basis of a 
starting building block. All steps of the design algorithm are deterministic, i.e. two runs of 
DOGS with identical parameters will deliver identical results. 
 
2.4 Scoring Function 
2.4.1 Graph Kernel Method 
The scoring function assesses the quality of a molecule with respect to the design objective. 
Products  of  each  stage  of  a  virtual  synthesis  pathway  (dummy  products,  intermediate 
products, final products) are evaluated by the same scoring function. DOGS uses a 2D graph 
kernel  method  (ISOAK
131)  for  scoring  the  designed  molecules.  The  graph  kernel  was 
originally  developed  for  similarity  searching  in  virtual  screening,  where  it  has  been 
successfully applied
132. ISOAK can be readily employed as a scoring function for ligand-
based de novo design, where, like in virtual screening, similarity to a given reference ligand 
forms the key objective for the design process. 
 
ISOAK computes the similarity of two molecules A and B based on their two-dimensional 
topological structure. Molecules are interpreted as graphs where atoms are represented as 
vertices and covalent bonds as edges between vertices (molecular graph). Hydrogen atoms 
and corresponding bonds are removed from the graph.  
In the first step, ISOAK computes a similarity value for each pair of vertices between A and 
B (Figure 10, step 1).  
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Figure 10. A similarity value for each pair of vertices between two labeled graphs is computed and stored in a 
matrix (step 1). An optimal assignment (step 2, dashed lines) of these vertex pairs maximizing the sum of 
similarities gives the final score. Some assignments are highlighted in black for better orientation. 
 
 
The similarity of two vertices is influenced by two terms. The first term compares the isolated 
vertices themselves based on their labels. In the context of molecular graphs, examples for 
meaningful vertex labels are atom types, element types, pharmacophoric features (discrete 
labels)  or  partial  charges  and  electronegativity  (continous  labels).  For  the  comparison  of 
vertex labels a function fvc(vl1,vl2) is needed to compute a numerical value for a pair of labels 
expressing their similarity. For discrete labels the Dirac kernel can be used. The Dirac kernel 
is a simple function returning ‘1’ if the two labels are identical and ‘0’ otherwise. The second 
term  of  vertex  similarity  takes  the  local  graph  environment  (surrounding  vertices)  into 
account.  The  basic  idea  behind  the  second  term i s  that  two  vertices  are  similar  if  their 
topological neighbors are similar. This recursive measurement incorporates vertex similarities 
of neighbored vertices as well as a comparison of connecting edges. For edge comparisons, 
for example, the Dirac kernel based on bond order labels (single, double, triple) is applied. 
The  recursive  nature  of  this  vertex  similarity  definition  is  expressed  by  an  iterative 
computation, where vertex similarities of pairs of neighbored atoms used in the i-th iteration 
are taken from results of the previous iteration i-1. Similarities of iteration 0 are initiated with 
a standard value, e.g. 1. In each iteration, the final similarity of two vertices is computed as a 
weighted sum of the two components, where the influence of each component is controlled by 
a parameter α (0 < α < 1). Component 1 (direct label comparison of vertices) is weighted by 
1-α, while component 2 (recursive neighborhood comparison) is weighted by α. Higher values 
of  α  therefore  increase  the  influence  of  the  topological  graph  neighborhood  on  vertex 
comparison (Figure 11). 
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Figure 11. The assignment of the left part (grey dashed lines) 
is  intuitive  since  the  respective  substructures  of  the  two 
molecules are identical. The assignment of the oxygen atom 
of the smaller molecule (black dashes lines, left) depends on 
the ISOAK parameter α. Higher values of α emphasize on the 
local n e i g h b o r h o o d  a n d  s h i f t  t h e  a s s i g n m e n t  a c c o r d i n g l y  
(right). 
 
 
As a second step (Figure 10, step 2), calculated vertex similarities are used to compute an 
optimal assignment: Each vertex of the smaller graph is assigned to exactly one vertex of the 
larger graph. The assignment is optimal in the sense that it maximizes the sum of similarities 
for the assigned vertex pairs. In other words, for each vertex of the smaller graph ISOAK 
finds exactly one corresponding vertex in the larger graph. Note that it is not possible for a 
vertex to appear in more than exactly one pair, i.e. a vertex of the smaller graph cannot be 
assigned to a vertex of the larger graph that has already been assigned to another vertex and 
vice versa. The total similarity of two graphs is finally computed as the sum of all similarities 
between the assigned vertices. 
 
2.4.2 Modification of the Graph Kernel Method 
The ISOAK kernel as published
131 and described above was slightly modified to adapt it to 
the requirements of DOGS. The following changes were introduced: 
 
Edge labels: An additional label ‘aromatic bond’ has been introduced to complement the 
existing labels ‘single bond’, ‘double bond’ and ‘triple bond’. The obvious advantage is that 
now  all  bonds  of  aromatic  systems  are  treated  equally,  which  better  reflects  their  actual 
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physical  properties.  The  original  implementation  distinguishes  between  single  and  double 
bonds  of  aromatic  systems,  which  can  lead  to  artificial  dissimilarity  between  identical 
substituted aromatic systems represented as different mesomeric resonance structures. The 
Dirac kernel based on these four discrete labels is applied to comparing edge labels. 
Vertex labels: Instead of labeling vertices with element types of corresponding atoms, the 
vertices  are  labeled  with  pharmacophoric  features  (pharmacophore  typing  is  described  in 
detail in section Pharmacophore typing below). Pharmacophore types describe atoms by their 
potential  molecular  interaction  with  a  receptor  molecule.  Depending  on  their  molecular 
environment, atoms of different element types can have the same pharmacophore type, which 
leads to an abstraction from the mere chemical nature of an atom, focusing on its potential to 
interact with a biological target. Since the goal of de novo design is to find novel chemical 
structures  while  keeping  the  desired  biological  effect  of  the  reference  ligand,  a 
pharmacophore  description  of  molecules  ought  to  be  beneficial  in  this  context.  For  the 
comparison of pharmacophore vertex labels the Dirac kernel is used. 
Graph reduction: Although designed for virtual screening of molecules, ISOAK is a general 
method  to  compare  labeled  graphs  of  any  kind.  The  reduced  graph  representation  of 
molecules was implemented as an alternative to the molecular graph introduced above. A 
reduced graph represents certain substructures of a molecule comprising more than one atom 
as single nodes: circular substructures as well as neighbored atoms sharing the same type 
‘lipophilic’ or ‘no type’ are condensed to one vertex. Bit vectors are used to label vertices of 
reduced  graphs  (labeling  and  vertex  comparison  are  described  in  detail  in  section  Graph 
reduction below). A reduced graph represents a more abstract molecule description and is 
supposed  to  complement  scoring  based  on  the  more  detailed  molecular  graph.  The  user 
chooses which of the two graph representations will be applied in a design run of DOGS.  
 
2.4.3 Pharmacophore Typing 
Each vertex of a molecular graph is labeled by one of seven pharmacophoric features (A: 
hydrogen bond acceptor, D: hydrogen bond donor, E: hydrogen bond donor & acceptor, P: 
positive  charge,  N:  negative  charge,  R:  aromatic,  0:  no  other  type)  depending  on  the 
corresponding atom of the molecule. Typing is performed by applying a set of substructure 
definitions expressed as MQL
133 strings (Table 2). All atoms not explicitly typed by one of 
these rules are assigned to have no type (‘0’). Table 2 presents the typing rules in the order 
they are applied to a molecule. The order is important because an atom that has already been 
typed by one rule will not be typed again. 	
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Table 2. Substructure definitions and corresponding typings. 
MQL substructure definition  Type  Example 
O[charge=-1]-N[charge=1]=O  0;0;0 
 
*[charge>0]  P 
 
*[charge<0]  N   
O=C-N[allHydrogens>0]  A;0;D 
 
O=C-N[allHydrogens=0]  A;0;0 
 
O=C-O[allHydrogens=0]  A;0;0 
 
N[allHydrogens>0 & !aromatic & !bound(-C=N) & 
!bound(-S=O)]  E 
 
O-H'  E   
Heavy'[!aromatic]-O-Heavy'[!aromatic]  A   
N[allHydrogens=0 & !{aromatic&totalConnections=3} 
& !{bound(-C=N) & !bound(=C)} & !{bound(-C:N) & 
!bound(=C)} & !bound(-S=O)] 
A   
O=*'[C|P|S|N]  A 
 
N[{allHydrogens=1 & aromatic} | {allHydrogens>0 & 
bound(-C=N)} | {allHydrogens>0 & bound(-S=O)}]  D 
 
N[aromatic]  R 
 
O[aromatic]  R 
 
C[aromatic]  R 
 
S[aromatic]  R 
 
Cl  L   
Br  L   
I  L   
C[!bound(~N)&!bound(~O)]~*'[C|F|Cl|Br|I|S]  L   
S[!bound(~N)&!bound(~O)]~*'[C|H]  L   
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2.4.4 Graph Reduction 
The graph reduction process is supposed to convert the molecule into an acyclic graph in 
order to represent it on a higher level of abstraction from its atomic structure. This is achieved 
by condensing certain substructures consisting of more than one atom to single graph vertices. 
The  reduced  graph  often  contains  fewer  vertices  than  the  number  of  heavy  atoms  in  the 
molecule (in contrast to the molecular graph, which always exhibits as many vertices as there 
are heavy atoms in the molecule). There are three cases in which atoms neighbored in a 
molecule  are  condensed  and  represented  by  one  vertex,  i.e. ( i)  cyclic  substructures,  (ii) 
clusters of atoms typed as ‘lipophilic’, and (iii) clusters of atoms typed as ‘no type’. The 
pharmacophore typing is identical to the one described in section Pharmacopohore Typing 
above. A cluster is defined as a set of atoms of the same type that form topological neighbors. 
Not all atoms of a cluster have to be directly connected via one bond but can also be linked 
via other atoms belonging to the same cluster. 
Cyclic substructures can consist of more than one ring. In the following, the term ‘ring’ will 
mean a cyclic substructure that is part of the smallest set of smallest rings (SSSR). Practically 
speaking, the SSSR is the set of all cyclic substructures with minimal numbers of atoms. All 
ring atoms must be covered by this set. A ring that only consists of ring atoms that can be 
completely covered by a combination of smaller rings will not be part of the SSSR (Scheme 
9). A more formal definition can be found in reference 134. 
 
 
 
Scheme 9. The ring on the left side is not part of the smallest set of smallest rings (SSSR) of the 
molecule in the center because the corresponding ring atoms can be covered by a combination of two 
smaller rings. The SSSR of the molecule is given on the right. 
 
 
The graph reduction algorithm represents each ring of the SSSR as one vertex. In case a ring 
system contains only atoms that do not belong to more than two rings (e.g. naphtalene) it is 
possible to represent each ring by a single vertex and connect them in such a way that their 
topological order in the molecule is preserved in the reduced graph (Figure 12A). There are, 
however, cases where this is impossible in a straightforward way. For example, it is not 
H
N
N
O
O
SSSR  not in  
SSSR 
N N
N	
 ﾠ 42 
possible to find an acyclic graph layout of all rings that are part of the SSSR for phenalene or 
adamantane which preserves their topological order in the molecule (Figure 12B). In order to 
solve this problem, the algorithm searches for atoms being part of more than two rings of the 
SSSR and combines these rings to one vertex in the reduced graph. Please note that this 
breaks  the  usual  ‘one-ring-one-vertex’  relation  between  the  molecule  and  the  respective 
reduced graph. Ring systems represented by a single vertex will be termed amalgamated in 
the following. 
In  order  to  distinguish  the  reduced  graph  representation  of  two  adjacent  rings  that  are 
connected by a bond and two rings that share atoms, the corresponding vertices of reduced 
graphs representing the rings are connected by an edge of order one (‘single bond’) in the 
former case and two (‘double bond’) in the latter case (Figure 12C). 
 
 
 
Figure  12.  A:  An  example  of a  r e d u c e d  g r a p h  r e p r e s e n t a t i o n .  D a s h e d  l i n e s  c o n n e c t  a t o ms  o r  rings o f  t h e  
molecule (left) with their corresponding vertex of the reduced graph (right). For clarity only some lines are 
shown. B: Examples of polycyclic substructures (‘amalgamated’) represented by only one vertex in the reduced 
graph. C: Edges of order two are used to connect fused rings (bottom) in order to distinguish the shown cases of 
neighbored rings in reduced graph representation. 
 
 
Labels of reduced graph vertices keep information about the atom(s) they represent. A bit 
vector of length nine stores which of the pharmacophore types are present in the respective 
substructure.  Each  of  the  seven  pharmacophore  types  is  represented  by  one  bit.  Two 
additional bits stand for ‘cyclic substructure’ and ‘amalgamated ring system’. A bit is set to 
‘1’ if the corresponding feature is present in the substructure, ‘0’ otherwise. In addition, a 
vertex also stores the number of atoms it represents (atom count). Accordingly, a benzene 
substructure would be converted to a single vertex labeled by a bit vector with bits set for 
‘ring’ and ‘aromatic’ and an atom count of six.  
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Bit vectors (bv) and atom counts (ac) are used to compute the similarity of two vertices A and 
B of reduced graphs. The similarity is computed by multiplying two components (equation 5).  
 
€ 
fvc(acA,acB,bvA,bvB) = sdFactor(acA,acB)*Ti(bvA,bvB)        (5) 
 
Term 1 (sdFactor) returns a value between 0 and 1 depending on the difference between the 
atom count values of compared vertices (Equation 6), computed as 
 
€ 
sdFactor(acA,acB) =
1 if acA − acB = 0
0.98 if acA − acB =1
0.9 if acA − acB = 2
0.8 if acA − acB = 3
0.5 if acA − acB = 4
0.3 if acA − acB = 5
0 if acA − acB > 5
⊧ 
⊨ 
⊪ 
⊪ 
⊪ 
⊪ 
⊪ 
⊩ 
⊪ 
⊪ 
⊪ 
⊪ 
⊪ 
.          (6) 
 
Term 2 is the Tanimoto index (Ti) for bit vector comparison (Equation 7), calculated as 
 
€ 
Ti(bvA,bvB) =
c
a+b −c
                (7) 
 
where c is the number of bits commonly set to 1 in both vectors, a is the number of bits set to 
1 in bvA and b is the number of bits set to 1 in bvB. Two identical bit vectors result in Ti = 1, 
while bit vectors with no set bits in common score with 0. Component sdFactor can be seen 
as a penalty function for atom count differences modulating the Tanimoto index. In case the 
atom count of compared vertices is equal (e.g. two six-membered rings are compared), fvc 
reduces to the Tanimoto index. If the difference between the atom counts exceeds five, fvc will 
return 0 regardless of the calculated Ti for the bit vectors.  
All other components of ISOAK including the edge comparison are identical to the molecular 
graph comparison. ISOAK can only processes graphs with a maximum vertex connectivity of 
six,  i.e.  a  vertex  of  a  graph  processed  by  ISOAK  must  not  have  more  than  six  directly 
connected neighbors. While this will not happen in molecular graphs (typically, no element 
that is present in druglike molecules will form more than six covalent bonds), such cases can 
occur in reduced graphs. For example, naphthalene is represented as a single vertex and offers 	
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up  to  eight  positions  for  substitution.  Molecules  containing  vertices  with  more  than  six 
neighbors in their reduced graph representation are excluded from subsequent steps and will 
be discarded. 
 
2.5 Assessment of Scaffold Similarity 
In order to assess the outcome of de novo design runs in terms of scaffold diversity and the 
software’s  potential  to  perform  scaffold  hops,  a  method  to  measure  distances  between 
scaffolds has been developed.  
As there is no general definition of the term ‘scaffold’,
135 the definition of graph frameworks 
according to Bemis and Murcko
136 has been selected to describe the molecular scaffold in this 
work.  Following  their  definition,  a  molecule’s  scaffold  is  extracted  by  keeping  all  cyclic 
substructures and the linker chains directly connecting them. Sidechains only connected to 
one or to no cyclic substructure are deleted. All retaining atoms are converted to carbon 
atoms, and all bonds are modified to single bonds (Scheme 10). 
 
 
 
 
Scheme  10.  Example  of s c a f f o l d  e x t r a c t i o n  a c c o r d i n g  t o  t h e  d e f i n i t i o n  o f  B e m i s  a n d  
Murcko.  The  scaffold  (right)  only  consists  of  the  ring  systems  and  the  linker  chains 
connecting them. All bonds have order one, and all atoms are converted to carbon atoms. 
 
 
Scaffold similarities are computed as Euclidian distances in a descriptor space spanned by 
three descriptors (‘number of rings’, ‘Petitjean’, ‘Kier1’) from MOE
128 (v2009.10). These 
descriptors show comparably low to moderate cross correlations on an external test set (Table 
3) and describe properties of the two-dimensional molecule framework. ‘Number of rings’ 
simply counts the number of all rings of the SSSR. ‘Kier1’ is the first of three kappa shape 
indices proposed by Hall and Kier.
137 It calculates a ratio between the number of atoms and 
bonds of a molecule [(#atoms-1)
2 / #bonds
2]. A slightly more elaborate measure for the 2D 
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shape of the molecule is computed by the ‘Petitjean’ descriptor
138: At first, an eccentricity 
value is determined for every atom of a molecule. It is defined as the longest of all shortest 
paths to every other atom in the molecule. The graph radius is the smallest atom eccentricity 
in the molecule and the graph diameter is the largest eccentricity value of the whole molecule. 
The descriptor is defined as (diameter-radius)/diameter. 
 
Table 3. Descriptor correlations are expressed as the Pearson correlation 
coefficient  (x100).  Calculations  were  performed o n  a  s e t  o f  s c a f f o l d s  
derived from ~11,000 bioactive molecules. 
   #Rings  Petitjean  Kier1 
#Rings  100  -  - 
Petitjean  21  100  - 
Kier1  53  27  100 
 
The external test set comprises about ~11,000 bioactive molecules with a molecular mass of 
<1000Da.
139 Scaffolds computed for this test set also served as a reference framework to 
establish a scaling procedure for descriptor values. Auto-scaling parameters (mean, standard 
deviation) extracted from test set descriptor values were applied to scale descriptor values of 
new compounds before computing Euclidian distances. This procedure adjusts the influence 
of each descriptor on the distance. The final distance between two scaffolds A and B was 
computed as given in equation (8). 
 
€ 
d(A,B) =
rings(A) − 4.30
1.12
−
rings(B) − 4.30
1.12
⊛ 
⊝ 
⊜ 
⊞ 
⊠ 
⊟ 
2
+
pj(A) −0.47
0.05
−
pj(B) −0.47
0.05
⊛ 
⊝ 
⊜ 
⊞ 
⊠ 
⊟ 
2
+
k1(A) −19.28
5.64
−
k1(B) −19.28
5.64
⊛ 
⊝ 
⊜ 
⊞ 
⊠ 
⊟ 
2
 (8) 
 
 
2.6 Implementation 
DOGS was implemented in Java
130 version 1.6 and uses the Chemistry Development Kit
140,141 
(CDK, version 1.0.2). Calculations were performed on an Apple Mac Pro with eight CPU 
cores (2 x 2.26GHz Quad-Core Intel Xeon) and 16GB RAM. 
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3 Results and Discussion 
 
DOGS was evaluated theoretically with respect to general characteristics of the program like 
runtime, number of generated molecules and scaffolds. Designed scaffolds were assessed for 
their similarity to the reference scaffold in order to analyze the program’s ability to propose 
ideas  for  novel  scaffolds.  DOGS  designs  were  also  investigated  for  general  properties  of 
interest  for  lead  candidates,  in  particular  druglikeness,  synthesizability  and  calculated 
logP(o/w). In order to be of practical relevance, a de novo design software tool must be able 
to come up with molecules that can be synthesized and already show druglike properties. 
Exemplary  compounds  generated  by  the  software  for  different  target  molecules  (trypsin, 
TGF-β1  receptor,  estrogen  receptor)  were  picked  out  and  discussed  with  regard  to  their 
pharmacophoric features in comparison to the respective reference ligand. Here, DOGS was 
tested  for  its  ability  to  generate  compounds  that  capture  the  main  features  of  the  seed 
molecule while being structurally distinct. Finally, the software was analyzed in two practical 
de novo design case studies (H4 receptor and γ-secretase). In both cases, proposed molecules 
were selected, synthesized and tested for their biological activity. 
 
3.1 Influence of Parameters on General Characteristics and Scaffold 
Diversity 
A goal of de novo design is to generate ideas for new scaffolds. In order to test DOGS for its 
ability to design compounds with scaffolds different from the scaffold of the reference ligand, 
result lists of runs started with different parameters were analyzed. The scaffold definition 
used in this investigation follows the one of Bemis and Murcko
136 (for details see section 
Assessment of Scaffold similarity in Materials and Methods). An inverse agonist of the human 
histamine H4-receptor served as reference ligand for all runs of this investigation (Scheme 
11).
142 The number of investigated start fragments was set to 200 in each case. For both graph 
representations, parameter α was varied from 0.1 to 0.9 in increments of 0.1, producing a total 
of 18 result lists. 
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Scheme  11.  An  inverse  agonist  of  the  histamine  receptor  served  as 
reference  ligand.
142  The  extracted  scaffold  on  the  right w a s  u s e d  t o  
analyze the similarity of scaffolds designed by DOGS.  
 
 
3.1.1 General characteristics 
Quantitative characteristics of each run are summarized in Figure 13. DOGS needed between 
8 and 15 hours to finish a complete run. Runtimes have the tendency to rise with higher α 
values, which can be observed for both graph representations (Figure 13, bottom charts). The 
reason  for  this  correlation  is  that  higher  α  values  increase  the  influence  of  the  graph 
neighborhood on vertex comparison, which leads to more computational iterations until the 
comparison process converges. An exception to the general trend is observed for α = 0.4 in 
reduced graph design mode. This is caused by the fact that all other runs were performed in 
parallel  with  other  jobs  on  the  same  machine,  while  this  run  was  performed  on  an  idle 
machine.  
In general, runtimes are comparable between the two molecule representations, giving rise to 
the  assumption  that  additional  computational  costs  caused  by  graph  reduction  are 
compensated by the faster comparison of less complex reduced graphs. Since the overall 
number of molecules designed during a run in reduced graph design mode is higher (Figure 
13,  top  charts),  the  overall  time  needed  to  score  a  single  molecule  is  lower  for  reduced 
graphs. Hence, the faster comparison even overcompensates the costs for graph reduction. 
The reason for an overall higher number of designed molecules in reduced graph mode may 
be addressed to the fact that the higher level of abstraction from the molecule increases the 
chance for different intermediate products receive the same score during design. In case more 
than one top scoring intermediate product occurs during construction, the process is split and 
more than one final product may be generated from the same start fragment.  
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Figure 13. Influence of parameter α on different performance characteristics of DOGS for molecular graph (A) 
and reduced graph (B) representation. Lines connecting single measurements are given for better overview and 
do not represent interpolations. 
 
 
The  number  of  duplicate  molecules  produced  during  a  run  is  widely  independent  of  the 
molecular  representation,  and  varies  only  slightly  with  changes  of  parameter  α.  It  is 
impossible that duplicate molecules also have identical synthesis pathways, since the list of 
synthesis building blocks does not contain duplicates. However, it can be expected that a 
large fraction of duplicates result from only slightly differing synthesis routes. For example, 
two synthesis pathways can be identical except for the initial building blocks: In case the 
starting  fragments  of  two  synthesis  pathways  only  differ  in  a  halogen  atom  (bromide 
exchanged against iodide), which is substituted by an azide in the first step in both cases, they 
do not represent alternative synthesis strategies. However, duplicates may also be produced 
by significantly differing synthesis pathways. In this case, they add valuable information to 
the result list because they point to alternative synthesis strategies. 
The number of unique scaffolds has the tendency to drop with elevating α values, although 
this is effect is observable most distinctly at different parameter ranges for the two graph 
representations (0.6-0.9 for molecular graph representation and 0.1-0.4 for reduced graph). 
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3.1.2 Scaffold Diversity 
In order to assess the influence of parameter α and the two different graph representations on 
the  quality  of  outcome  with  respect  to  scaffold  diversity,  a  numerical  representation  of 
scaffolds was used (for details see section Assessment of Scaffold Similarity in Materials and 
Methods). The descriptor representation allows for distance calculation between scaffolds of 
designed  molecules  and  the  reference  scaffold.  Figure  14  presents  statistical  parameters 
(median,  average  and  standard  deviation)  of  scaffold  distance  distributions  as  well  as 
additional characteristics related with scaffold generation derived from analyzes of the 18 
DOGS runs investigated in the former section. 
 
 
Figure 14. Influence of parameter α on characteristics and distribution of distances between designed scaffolds 
and  the  reference  scaffold  (A:  molecular  graph  representation;  B:  reduced  graph  representation). L i n e s  
connecting single measurements are given for better overview and do not represent interpolations. 
 
 
Median and average values of scaffold distance distributions only marginally differ between 
molecular graph and reduced graph representations at the same α level. The same holds true 
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when  comparing  different  α  levels  of  the  same  graph  representation.  Standard  deviations 
slightly decrease with increasing α for molecular graph scoring. High α values in combination 
with the reduced graph design mode (0.7-0.9) produce scaffold distributions with increased 
standard deviations. 
The number of molecules exhibiting the same scaffold as the reference molecule can serve as 
an  evidence  whether  parameter  combinations  are  able  to  generate  close  analogs  of  the 
reference molecule. In general, this is not the intention of de novo design, as the scope is to 
come up with innovative scaffolds. On the other hand, a low number of scaffold re-designs 
can be seen as an indicator that the algorithm designs ‘around’ the seed scaffold in scaffold 
space. In the given example, re-design of the reference scaffold is enhanced at higher levels of 
α for both molecule representations (0.6-0.8), while it is not observable at α = 0.9. A possible 
explanation for this observation might be that such high levels of α influence the selection of 
initial building blocks in a way that they do not offer the potential to be transformed by 
suitable reactions to exhibit the reference scaffold. 
It is of greater interest for de novo design programs to be able to produce new scaffolds that 
feature pharmacophore and shape similarity compared to the seed. In order to test DOGS for 
the ability to propose new scaffolds similar to the reference, the number of scaffolds that 
structurally differ from the reference scaffold but exhibit minimal distance in the descriptor 
space (distance = 0) was counted in each result list (Figure 14). DOGS was able to at least 
design one new scaffold with distance 0 in every run except for one (α = 0.2, reduced graph 
mode).  The  molecular  graph  representation  always  produced  at  least  as  many  new  ‘0-
distance’ scaffolds on equal α levels as the reduced graph mode, in 66% of the cases even 
more. 
 
Summarizing, these analyses do not give clear evidence on preferable parameters for DOGS 
runs. Visual inspection of several result lists based on different reference ligands revealed that 
molecular graph representation is preferably combined with α values in the high range (0.7-
0.9). This is supported by the fact that the default setting for α is 0.875 in the original version 
of ISOAK for virtual screening.
131,132 This method is almost identical to the molecular graph 
mode used here, as it also operates on topological molecule graphs. In contrast, reduced graph 
design works better on α values in the low to mid range (around 0.4). High α values tend to 
produce  molecules  exhibiting  little  similarity  to  the  reference.  This  subjective  finding  is 
supported  by  the  fact  that  exceptionally  high  standard  deviations  of  scaffold  distance 
distributions occur at these combinations of parameters (Figure 14B), giving evidence that 	
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more scaffolds of larger distance to the reference are designed in these cases. The fact that 
result structures of the reduced graph representation were deemed to be more reasonable at 
lower α values than for the molecular graph may be addressed to the fact that ring systems 
commonly occure in druglike molecules and therefore play an important role in objective 
similarity measurements as well as in subjective human cognition. Reduced graphs represent 
rings  or  even  ring  systems  by  single  vertices.  By  reducing  the  influence  of  the  graph 
environment on vertex comparison via lower α values, ISOAK emphasized a direct vertex 
comparison, which means direct matching of rings in the case of reduced graphs. In contrast, 
matching of complete rings is enhanced by high α values in molecular graph design mode, 
since this forces ISOAK to put focus on the environment of compared atoms and incorporate 
connected ring atoms into vertex comparison. 
 
In general, one might expect a more abstract molecule representation (reduced graph) to lead 
to more distant and diverse scaffold designs compared to a more detailed description of a 
molecule (molecular graph). Therefore, it might seem counterintuitive that design runs based 
on reduced graph representation do not breed scaffolds with a higher average distance to the 
reference than the molecular graph (Figure 14). It should be stated that the results of this 
investigation and drawn conclusions only hold for the selected descriptor space encoding the 
scaffolds.  Future  work  needs  to  address  whether  similar  observations  can  be  made  for 
different scaffold representations. 
 
For  further  analysis  of  the  influence  of  molecule  representation  on  scaffold  generation, 
another study of scaffold comparison based directly on the scaffold structures (instead of an 
abstraction by molecular descriptors) was performed. Four DOGS runs (reduced graph and 
molecular  graph,  each  on  α=0.875  and  α=0.4)  were  carried  out  based  on  two  different 
reference ligands: an inhibitor of the human transforming growth factor (TGF) β1 receptor
143 
and the hH4R antagonist JNJ7777120
144 (Scheme 12). For these eight runs, distributions of 
scaffold distances to the reference scaffolds exhibit the same behavior as described in the 
former analysis for the hH4R inverse agonist: no significant difference between distributions 
of reduced graph design and molecular graph design is observable (Figure 15). 
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Scheme 12. Reference ligands (a TGF β1 receptor inhibitor
143 and a hH4-
receptor antagonist
144) and extracted scaffolds. 
 
 
 
 
Figure  15.  Distributions  of  distances  between  designed  scaffolds  and  the 
respective  reference  scaffold  for  eight  DOGS  runs ( left:  TGF-β1  receptor 
inhibitor; right: JNJ 7777120; mG = molecular graph; rG = reduced graph). 
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Figure 16. Overlaps of scaffold lists from runs based on molecular graph (mG) and reduced graph (rG) scoring 
(A: TGF-β1 receptor inhibitor; B: JNJ 7777120). The total number of scaffolds found in a run is given next to 
the corresponding circle. Figures inside of circle fractions describe numbers of scaffolds. Overlaps represent 
scaffolds constructed by both design modes. Examples of scaffolds for each fraction are given below. 
 
 
Nevertheless, a comparison of the scaffold lists produced with the two different abstraction 
levels on the same α value revealed that – albeit showing comparable distance distributions 
around the scaffold – they exhibit only small to moderate overlaps (Figure 16). This finding 
suggests that while reduced graph scoring did not jump farther away in the spanned descriptor 
scaffold space, it jumped into directions in structural scaffold space that considerably differ 
from those followed by molecular graph scoring. This leads to the conclusion that results 
produced on different abstraction levels of molecule representation are complementary. It is 
therefore worthwhile to apply both design modes to yield a richer pool of ideas for new 
scaffolds. 
 
3.2 Property Analysis of Designed Compounds 
De novo design programs are supposed to suggest compounds exhibiting druglike properties. 
Although  successful  de  novo  design  campaigns  will  likely  be  followed  by  a  process  of 
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structural  optimization  in  order  to  improve  pharmacokinetic  properties  of  designed 
compounds, it is evident that designed compounds should already show druglike properties 
themselves.  Lipinski and coworkers have proposed four simple rules (‘rule of 5’),
145 which 
have found wide acceptance as crude criteria for an estimation of oral bioavailability. These 
rules define negative guiding principles: with each additional failed criterion, the probability 
of showing poor absorption or permeation rises, which might lead to attrition in later steps of 
the drug development process. It is important to be aware of the fact that the ‘rule of 5’ 
present soft filters. Failing one of the filters does not necessarily mean that a molecule is not 
druglike  and  has  no  chance  to  become  a  drug.  In  fact,  not  all  marketed  drugs  and  drug 
candidates pass each of Lipinski’s rules.
119 
In order to assess the druglikeness of DOGS designs, ‘rule of 5’ violations of 1,767 molecules 
originating from ten DOGS runs were computed using the descriptor implemented in the 
software MOE. Five trypsin inhibitors served as reference ligands for these runs (Scheme 13).  
 
 
 
Scheme  13. F i v e  t r y p s i n  i n h i b i t o r s  s e r v i n g  a s  reference  compounds  for  DOGS  design  runs 
(Camostat
146, NAPAMP
147, Efegatran
148, Patamostat
149,150, UK-156406
151). 
 
 
For  each  reference,  one  run  based  on  the  molecular  graph  (α=0.875)  and  a  second  run 
applying the reduced graph representation (α=0.4) was performed. Strikingly, an analysis of 
‘rule  of  5’  violations  shows  that  most  of  the  compounds  constructed  by  DOGS  (78.5%) 
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violate  less  than  two  rules  (Figure  17).  Only  52  proposed  molecules  (3%)  show  three 
violations. The distribution of designed compounds mirrors the one of the reference ligands. 
A second analysis of druglikeness of DOGS designs was carried out for the same set of 
designs using an artificial neural network.
152 This classifier had been trained on a set of drugs 
and non-drugs to score molecules between 0 (low druglikeness) and 1 (high druglikeness). 
Out of the 1,767 molecules designed by DOGS 904 (51%) receive a score >0.8 (Figure 18). 
 
 
 
 
Figure 17. Distribution of ‘rule of 5’ violations of compounds designed by DOGS ( left) and of respective 
reference compounds (right).  
 
 
 
 
Figure  18. D i s t r i b u t i o n  o f  druglikeness  scores  of  compounds  designed  by  DOGS  (left)  and  the  reference 
compounds of respective runs (right). Scores have been computed by a trained classifier (1 = high druglikeness). 
 
 
Besides this result it is eye-catching that a considerable number of molecules (436) receive a 
poor druglikeness score below 0.1. This fact is less surprising if one considers that the set of 
reference compounds also contains a molecule deemed to be not druglike (Patamostat, score = 
0.11).  Compounds  designed  to  maximize  similarity  to  this  reference  can  be  expected  to 
receive poor druglikeness scores as well. 
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Another  relevant  property  for  drug  candidate  molecules  is  lipophilicity.
153 A   common 
parameter  closely  related t o   this  property  is  the  octanol-water  partition  coefficient 
(logP(o/w)).
154 One of the Lipinski rules states that logP(o/w) values greater than 5 enhance 
the chance that a molecule will be poorly absorbed.
145 The logP(o/w) was calculated for the 
five trypsin reference ligands and the molecules designed by DOGS using the ‘logP(o/w)’ 
descriptor implemented in MOE
128 (Figure 19).  
 
 
 
Figure 19. Distribution of calculated logP(o/w) scores of compounds designed by DOGS (left) and the reference 
compounds of respective runs (right).  
 
 
The distribution of calculated logP(o/w) values of DOGS designs approximates a unimodal 
distribution  centered  around  values  between  2  and  3.  This  is  in  agreement  with  the 
distribution of values calculated for the reference ligands. DOGS was able to mimic this 
property of the references in the designed compounds, although it is not explicitly considered 
during the design. 
 
It is of critical importance that molecules designed in silico not only exhibit desired properties 
but  are a l s o   amenable  to  chemical  synthesis  in  order  to  be  of  practical  value  for  drug 
discovery projects. A molecular descriptor (‘rsynth’) implemented in the software package 
MOE
128 estimates synthesizability of molecules by the fraction of heavy atoms that can be 
traced back to starting material fragments resulting from retrosynthesis disconnection rules. A 
score  of  1  means  full  coverage  of  atoms  and  expected  high  synthesizability.  The  rsynth 
descriptor was calculated for both the reference set and the set of de novo designed molecules 
(Figure 20). The majority of DOGS designs is deemed synthesizable (77% of compounds 
receive a score of >0.9). 
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Figure 20. Distribution of estimated synthesizability scores of compounds designed by DOGS (left) and the 
reference compounds of respective runs (right). A score of 1 means perfect expected synthesizability. 
 
 
Most of the remaining designs receive scores between 0.4 and 0.8. Reference compound UK-
156406 is scored comparably low (rsynth = 0.37). A total of 35.5% (141 of 397) of all DOGS 
designs scoring below 0.8 originate form this reference ligand, which exceeds an expected 
fraction of 20% assuming that low-scoring designs come from all five references in equal 
parts. That means low synthesizability scores are enriched for molecules originating from a 
reference compound that is scored unfavorable as well.  
In  conclusion,  this  result  may  be  considered  a  success  of  the  DOGS  approach  to  obtain 
synthesizability of de novo designed compounds. 
 
Summarizing, DOGS is able to design overall druglike and chemically plausible molecules 
with a chance of being amenable to chemical synthesis. The proposed molecules resemble the 
reference compounds in properties that are not explicitly considered by the scoring function. 
 
3.3 Exemplary DOGS Designs  
3.3.1 Trypsin 
Trypsin is a serine protease found in the digestive system of vertebrates. Its enzymatic activity 
comprises the cleavage of amide bonds in the protein backbone. Cleavage sites of trypsin are 
characterized by lying next to basic amino acids (arginine, lysine) in C-terminal direction.
155 
The main reason for cleavage site specificity of trypsin is the S1 binding pocket (Figure 21), 
which is selectively filled by basic amino acid sidechains to interact with an aspartate residue 
at its bottom.
155 Inhibition of trypsin itself is of little pharmaceutical interest, but can be used 
as  an  example  for  case  studies  on  serine  proteases.  From  a  pharmacological p erspective, 
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trypsin represents an off-target for drug discovery projects directed to therapeutically relevant 
serine proteases like thrombin and factor Xa.
156 
 
 
 
 
Figure  21. C r y s t a l  s t r u c t u r e  o f  human  trypsin  I  (pdb-
identifier 1trn; only one of the two monomers is shown). 
An aspartate residue (red surface area) is located at the 
bottom of the S1 pocket. 
 
 
Two examples of structures proposed by DOGS as potential trypsin inhibitors are given in 
Scheme  14.  Structures  3  and  4  were  obtained  from  design  runs  based  on  Efegatran  and 
Camostat (200 start building blocks, α = 0.4 for reduced graph, α = 0.875 for molecular 
graph).  Compound  3  originates  from  the  reference  ligand  Efegatran.  It  exhibits  a  central 
sulfonamide moiety, which is not present in the reference molecule but can be found in other 
trypsin  inhibitors  (for  example  in  NAPAMP  and  UK-156406,  Scheme  13).  That  means 
DOGS replaced a substructure of the reference by a structurally different but presumably 
isofunctional fragment, which is present in other known actives. The guanidinium sidechain 
of Efegatran was exchanged with the close structural analog 3-methylguanidinium. 
S1 pocket 	
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Scheme 14. Compounds 3 and 4 have been proposed by the software as potential trypsin inhibitors. Reference 
ligands (Efegatran
148, Camostat
146) and suggested synthesis pathways are presented for both candidate structures. 
 
 
The overall composition of functional groups in 3 resembles the arrangement of the reference. 
The synthesis route proposed by DOGS will probably have to be augmented by the use of 
protection groups. For example, the formation of the ester bond in the last synthesis step can 
be disturbed by the competing formation of an amide bond with the primary amine of educt 2-
aminocyclopentanol. Protection of the amine group could remedy this difficulty. Note that 
DOGS  currently  does  not  consider  protection  groups.  Competing  side  reactions  are  only 
addressed by avoiding multiple occurrences of the same functional group in an educt. 
Compound  4  has  been  derived  from  Camostat.  Compared  with  the  former  example  of 
molecule 3, molecule 4 is generally more distinct from its reference compound with respect to 
the  molecular  structure.  While  the  guanidinium  group  of  the  reference  is  preserved,  it  is 
connected  to  an  alkyl  chain  instead  of  a  phenyl  ring.  Alkyl  linkers  connecting  the 
guanidinium  group  can  also  be  found  in  the  reference  Efegatran  and  in  the  sidechain  of 
arginine, a ‘natural’ ligand of the trypsin S1 pocket. An aromatic substructure in distance to 
the part addressing the S1 pocket is another feature that can be found in other trypsin ligands 
as well as in compound 4 (compare NAPAMP, Scheme 13). Albeit showing considerable 
structural difference to the reference compound it originated from, compound 4 represents a 
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promising  candidate  structure  due  to  its  arginine-like  sidechain  in  combination  with  the 
distant aromatic system. In addition, it must be stated that the design of isofunctional but 
structurally  different  molecules  is  one  of  the  goals  of  de  novo  design.  Compound  4  is 
promising with respect to its potential to fulfill this demand. 
Bioisosteric replacement
135 of functional groups is a key to successful de novo design. In 
order  totest  DOGS  for  its  ability  to  perform  bioisosteric  replacement,  the  list  of  1,767 
potential trypsin ligands designed by the software (resulting from ten runs based on five 
trypsin  references)  was  ranked  according  to  the  scores  assigned  by  DOGS.  The  top  200 
molecules  were  analyzed  for  functional  groups  that  replace  the  sidechains  of  reference 
compounds addressing the S1 pocket (guanidinium and benzamidine, Scheme 15). 
 
 
Scheme 15. Sidechains addressing the S1 pocket found in the five reference compounds (left) and 
surrogates suggested by DOGS found in top-scored 200 designs (right). 
 
 
Starting at rank position 78 (compounds on higher ranks exhibit one of the fragments present 
in  the  references),  DOGS  suggested  eleven  different  sidechains  replacing  the  reference 
fragments in the top 200 designs. Most of them offer the possibility to interact with the 
negatively charged aspartate sidechain of the S1 binding pocket of trypsin by a positively 
ionizable nitrogen atom. The terminal urea group and the two aromatic fragments (pyrimidin-
2-amine and pyridin-2-amine) represent exceptions, where the nitrogen will likely not carry a 
positive charge. The formation of this salt bridge is a known key interaction inside the S1 
pocket.
155 Albeit the formation of the salt bridge is unlikely for these three fragments, they are 
still able to form a hydrogen bond to the aspartate sidechain. In fact, both pyrimidin-2-amine 
and pyridin-2-amine can be found in known trypsin inhibitors as S1 adressing sidechains 
(Scheme 16).  
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Scheme  16. K n o w n  i nhibitors  of  trypsin  showing  pyrimidin-2-amine
157  (left)  and  the 
pyridin-2-amine
158 (right) sidechains (grey circles). These moieties were also present in 
DOGS designs suggested as bioisosters for sidechains of the reference ligands addressing 
the S1 pocket of trypsin. 
 
 
In  addition,  the  list  of  proposed  sidechains  contains  an  alkyl  chain  carrying  a  terminal 
nitrogen. This fragment resembles the sidechain of lysine – one of the ‘natural’ ligands filling 
the S1 pocket during peptide bond cleavage. 
In  summary,  DOGS  was  able  to  suggest  some  reasonable  potential  bioisosters  for 
substructures  of  reference  ligands  addressing  the  S1  pocket  of  trypsin  including 
experimentally validates examples. 
 
3.3.2 Transforming Growth Factor β1 Receptor 
The transforming growth factor (TGF) β1 receptor is a transmembrane protein involved in the 
transduction  of  extracellular  signals  into  the  cell.
143  An  intracellular  kinase  domain i s  
activated upon extracellular binding of the cytokine TGF-β1.
143 The receptor is involved in a 
number of processes like cell differentiation, growth and embryonic development. For this 
reason, it may play a role in a number of diseases including cancer and wound healing.
143 
The reference ligand already introduced in Scheme 12 (top) served as a seed for two runs of 
DOGS to suggest potential ligands of the human TGF-β1 receptor kinase domain (run 1: 
reduced graph, α = 0.4; run 2: molecular graph, α = 0.875). A selection of designed molecules 
is presented in Scheme 17.  
The  overall  arrangement  of  aromatic  systems  of  the  reference  is  kept  in  the  designed 
molecules, while each structure exhibits a modification compared to the reference. Except for 
one example, the central ring system is a product of the synthesis pathway. Synthesis routes 
comprise only one or two steps and can be deemed traceable. 
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Scheme  17. M o l e c u l e s  5-8 w e r e  p r o p o s e d  b y  D O G S  together  with  presented  synthesis  plans  based  on  an 
inhibitor of the human TGF-β1 receptor.
143 
 
 
3.3.3 Estrogen Receptor 
Raloxifene is a potent modulator of the human estrogen receptor (ER).
159 It is approved as a 
drug for the treatment of osteoporosis in postmenopausal women.
160 DOGS designed two lists 
of ligand candidates for the human ER based on Raloxifene as a reference (run 1: reduced 
graph, α = 0.4; run 2: molecular graph, α = 0.8). Two exemplary structures from these lists are 
shown in Scheme 18. 
As in the former example of TGF-β1 receptor ligand design, DOGS was able to suggest 
molecules  exhibiting  distinct  similarity  to  the  reference  in  the  overall  composition  of 
structural elements. The number of rings as well as their topological arrangement in designed 
molecules  is  comparable  to  Raloxifene.  This  is  especially  the  case  for  compound  10. 
Molecule 9 introduces a shift in the localization of an aromatic system (furan) to form a 
spacer  between  the  benzimidazole  and  a  phenyl  ring.  Altogether,  10  exhibits  a  higher 
structural  similarity  to  the  reference  ligand  than  9.  The  sidechain  carrying  a  terminal 
piperidine is almost identical to the one of Raloxifene (only a carbonyl group is missing), 
while the linker is completely replaced with an alkyl chain in 9. This might cause a loss of 
O
N N
N
O
HO
N N
H2N N
OH
N
N
HN O
N
N
N
+
N
HN
OH
O
+
N N
H2N N
OH
N
N
N NH
N
N
N
N
N
NH
H2N
O
N N
N
NH N
+ N B
HO
HO
+
5 
6 
7 
8 
N
NH
N
N
TGF-!1 receptor inhibitor 
IC50 = 51 nM 
DOGS 
+ 
+ 
+ 
+ 
H2N
OH
H2N
OH	
 ﾠ 63 
potential interactions with the receptor in case atoms of this linker form interactions. While 
the exchange of a hydroxy group against a methoxy substituent in 9 retains the property of a 
hydrogen bond acceptor, the second hydroxy group is replaced by a nitro group. Effects of 
this exchange heavily depend on the kind and energetic contribution of the interaction formed 
between  the  replaced  hydroxy  group  and  the  receptor.  Compound  10  replaces  a  hydroxy 
group of the reference with a fluorine atom. Fluorine has been reported to act as a hydrogen 
bond acceptor in some cases, albeit weaker than an oxygen of a hydroxy group.
161 Effects of 
these modifications on the biological activity have to be elucidated by practical synthesis and 
testing. The synthesis pathway of 10 seems feasible and simple. The ring closing reaction of 
compound 9 might be difficult because of the highly substituted educts. 
 
 
 
Scheme 18. Molecules 9 and 10 were proposed by DOGS together with presented synthesis plans based on 
Raloxifene, a modulator of the human estrogen receptor.
159 Where available, general names of reactions are 
given next to reaction arrows. 
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3.4 Practical Evaluation of the Software 
3.4.1 Human γ-secretase 
DOGS was employed to propose candidate structures as new modulators of the human γ-
secretase. This target is responsible for the production of potentially toxic amyloid-β (Aβ) 42 
peptides.
162  Extracellular  accumulation  and  formation  of  amyloid  plaques  is  the  primary 
pathological event in Alzheimer’s disease.
163 Oligomerisation of Aβ42 peptides is believed to 
be a pivotal step in plaque formation.
162 Modulators of the γ-secretase are supposed to shift 
the  product  ratio  of  amyloid  precursor  protein  processing  towards  shorter,  non-toxic  Aβ 
fragments like Aβ38 or Aβ40.
162 
Four  different  reference  ligands  known  to  modulate  γ-secretase  were  selected.  For e a c h  
reference compound, two DOGS runs (molecular graph representation, α = 0.875; reduced 
graph representation, α = 0.4) were performed. Each of the eight resulting lists of DOGS 
designs was re-scored after the run by a CATS
122 similarity analysis (Euclidian distance in the 
space  spanned  by  the  descriptor).  Compounds  of  each  list  as  well  as  the  corresponding 
reference ligand were encoded by the CATS descriptor and subsequently ranked according to 
their distance to the reference in order to get an additional criterion for prioritization. Re-
ranked lists were visually inspected and two promising ligand candidates 11 and 12 were 
selected for synthesis (Scheme 19). Criteria for compound selection were (in their order of 
importance) (i) the subjective rating of the molecular structure by a medicinal chemist, (ii) 
ease and plausibility of proposed synthesis route, and (iii) CATS as well as ISOAK scores. 
 
 
Scheme  19. C a n d i d a t e  s t r u c t u r e s   11 a n d  12 p r o p o s e d  b y  D O G S  a s  potential m o d u l a t o r s  o f  t h e  h u m a n  γ-
secretase.  Synthesis  plans  were  suggested  by  the  software a n d  successfully  pursuit.  Molecules  11 a n d  12 
originate from distinct runs based on different reference ligands.
163 IC50 values are determined by two separate 
dose  response  experiments.  Concentrations  of  secreted  amyloid  peptides  are  detected  separately  in  cell 
supernatants by labeled antibodies and electrochemiluminescence. 
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Synthesis  plans  were  readily  traceable  as  suggested  by  the  software.  One-step  reactions 
yielded the products in both cases. DOGS was able to design compounds not only deemed 
promising by medicinal chemists, but also proved to be synthesizable as suggested. 
Synthesized compounds were tested for their ability to modulate the human γ-secretase by 
measuring  the  concentrations  of  amyloid  peptides  Aβ38,  Aβ40,  and  Aβ42  in  cell 
supernatants. Cell lines overexpressing human γ-secretase and the amyloid precursor protein 
are treated with the compound. Labeled antibodies specific for each of the three peptides are 
used  to  determine  their  levels  of  concentration  in  the  cell  supernatant  in  a  liquid  phase 
electrochemiluminescence  assay.
164  First  results  report  modulation  of  γ-secretase  activity 
(Figure 22). Both compounds shift the product ratio towards higher levels of Aβ42. Although 
this  is  not  the  effect  intended  for  a  potential  treatment  of  Alzheimer’s  disease,  this  first 
practical evaluation of DOGS can be deemed successful. For both selected compounds the 
suggested synthesis plan was readily pursuable and a modulation of target activity could be 
observed.  These  ligands  can  serve  as  starting  points  for  an  optimization  of  the 
pharmacological profile by structural modification. 
 
 
 
Figure  22. M o d u l a t i o n  o f  γ -secretase  activity  by  designed  ligands.  Both 
compounds modulate the activity of γ-secretase by a shift of product ratio towards 
higher levels of Aβ42. 
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3.4.2 Human Histamine H4-Receptor 
Histamine is a biogenic amine involved in a plethora of signaling pathways as a messenger. 
Four  subtypes  of  histamine  receptors  (hH1R  –  hH4R)  are  known  in  human.  All  subtypes 
belong to class A (rhodopsin-like) of the GPCR super family.
142 Some antagonists of hH1R 
and hH2R are approved drugs for the treatment of allergic reactions and ulcer. Clinical trials 
of hH3R antagonists for the therapy of neuronal diseases like epilepsy, schizophrenia and 
sleep/wake disorder are currently in progress.
165 Although subtypes 3 and 4 show the highest 
intra-familial  similarity  (37%  sequence  identity),  selective  hH4R  antagonists  have  been 
identified.  Preclinical  trials  reveal  their  potential  therapeutic  application  in  allergy, 
inflammation, autoimmune disorders and cancer.
165 
DOGS was applied to give ideas for new selective antagonists or inverse agonists of hH4R. 
For this purpose, two reference ligands (an inverse agonist and an antagonist) were employed 
as seed structures (Scheme 20). For each reference, the molecular graph representation (α = 
0.875) as well as the reduced graph representation (α = 0.4) was applied, resulting in four 
runs. Visual inspection of result lists together with medicinal chemists familiar with the target 
led to a prioritization of compounds. Three examples of top rated designs are presented in 
Scheme 20.  
 
 
Scheme 20. Molecules 13 and 14 were proposed by DOGS based on an inverse agonist of hH4R
142 (A). 
Compound 15 is a design originating from the antagonist JNJ 7777120 of the same target
144 (B). General 
names of reactions are provided below reaction arrows if available. 
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N-methylpiperazine is present in both references and represents a chemical moiety that is 
often  used  as  a  basic  head  group  in H 4  receptor  ligands.
166  The  positive  charge  of  basic 
amines  is  believed  to  form  a  key  interaction  to  a  negatively  charged  sidechain  of  the 
protein.
167 While in compound 13 the N-methylpiperazine moiety is preserved, it is replaced 
in 14 and 15 by isofunctional groups. Both of them represent aliphatic rings exhibiting basic 
amines,  which  provide  the  chance  to  undergo  the  charge-mediated  interaction  with  the 
receptor. Localization of aromatic ring systems of reference compounds is also approximately 
kept within the proposed structures. Compound 15 is of special interest because it combines 
two structural elements that can be found in reported H4R ligands: an alkylic linker chain with 
an ether bridge connecting and a central triazole ring (Scheme 21). Notably, both structural 
elements are not present in the reference compound. The moderate binding energy of the 
triazole-carrying ligand 16 (Ki = 35 µM) may be caused by a missing hydrogen bond acceptor 
in  the  central  part.  This  pharmacophoric  feature  is  also  believed  to  play  a  role  in  the 
interaction with binding pocket of H4R.
167 The oxygen atom of the ether bridge present in 
designed compound 15 and H4R ligand 17 is able to act as a hydrogen bond acceptor. The 
ISOAK  scoring  function  of  DOGS  assigns  this  oxygen  to  the  carbonyl  oxygen  of  the 
reference, which can act as a hydrogen bond acceptor as well. 
 
 
 
Scheme  21. H i g h l i g h t e d  f e a t u r e s  o f  t w o  hH4R  ligands  (compound  16
142:  central 
triazole ring; compound 17
168: alkyl linker chain with ether bridge) are combined in 
designed compound 15. None of these features is present in the reference ligand. 
 
 
 
In order to test for the hypothesis that the combination of features found in compound 15 
might lead to affinity to hH4R, compound 15 was selected for synthesis and testing. The 
synthetic  procedure  was  realized  exactly  as  suggested  by  the  software  (Scheme  22). 
Analytical spectra of intermediate products 18 and 19 as well as of compound 15 can be 
found in the supplement. 
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Scheme 22. Synthesis of compound 15 as proposed by the software. 
 
 
Compound  18 ( 1-(2-(2-chloroethoxy)ethyl)piperazine).  Educt  2-(2-(piperazin-1-
yl)ethoxy)ethanol (1 eq.) was precipitated with 5N isopropylic HCl (3 eq.). The salt was 
filtered off and dried. In order to substitute the hydroxy group with chloride, the salt (1 eq.) 
was  dissolved  in  toluene,  and  thionyl  chloride  (3  eq.)  was  added  slowly  under  cooling 
conditions (ice bath). After heating to 70°C for 10 minutes, the mixture was stirred for 3h at 
60°C under argon atmosphere. The formed precipitate was filtered off and dried in vacuo to 
yield a yellowish-white solid. MS (ESI
+): m/z = 192.91 [M+H]
+. 
1H NMR (MeOD, 400.13 
MHz): δ 3.57 (t, 2H, J = 4.9 Hz), 3.63 (m, 8H), 3.77 (t, 2H, J = 5.6 Hz), 3.85 (t, 2H, J = 5.7 
Hz), 3.97 (t, 2H, J = 4.9 Hz). 
 
Compound 19 (1-(2-(2-azidoethoxy)ethyl)piperazine). Compound 18 (1 eq.) and sodium 
azide  (2  eq.)  were  dissolved  in  DMSO.  The  mixture  was  stirred  for  42h  at  100°C.  The 
precipitated  white  solid  was  removed  by  filtration.  The  orange  filtrate  was  diluted  with 
dichloromethane and extracted with 2N NaOH (three times). After removal of the solvent, the 
brown  product  (oil)  was  dried  in  vacuo.  MS  (ESI
+):  m/z  =  199.93  [M  +  H]
+. 
1H  NMR 
(DMSO-d6, 400.13 MHz): δ 2.34 (t, 4H, J = 3.9 Hz), 2.44 (t, 2H, J = 5.9 Hz), 2.69 (t, 4H, J = 
4.7 Hz), 3.38 (t, 2H, J = 4.9 Hz), 3.54 (t, 2H, J = 5.9 Hz), 3.58 (t, 2H, J = 4.9 Hz). 
 
Compound  15 ( 1-(2-(2-(4-(3-chlorophenyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethyl)piperazine).  Compound  19  (1  eq.)  and  1-chloro-3-ethynylbenzene  (1eq.) 
were  dissolved  in  a  mixture  of  water  and  isopropyl  alcohol  (1:1)  and  placed  in  a  5ml 
microwave  vial.  Copper(I)-iodide  (0.1  eq)  was  added  and  the  mixture  was  heated  in  a 
microwave  oven  (Biotage  Initiator,  100W,  125°C,  20min,  absorption  level:  high).  The 
mixture was extracted three times with dichloromethane and 2N NaOH. After removal of the 
solvent, the remaining oil was purified by flash column chromatography (Biotage Isolera 
One) to yield a light brown oil. MS (ESI+): m/z = 335.82 [M + H]
+. 
1H NMR (DMSO-d6, 
400.13 MHz): δ 2.25 (t, 4H, J = 3.9 Hz), 2.39 (t, 2H, J = 5.7 Hz), 2.60 (t, 4H, J = 5 Hz), 3.52 
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(t, 2H, J = 5.7 Hz), 3.84 (t, 2H, J = 5.2 Hz), 4.57 (t, 2H, J = 5.2 Hz), 7.40 (ddd, 1H, J1 = 1.1 
Hz, J2 =2.2 Hz, J3 = 8.0 Hz), 7.49 (t, 1H, J = 7.9 Hz), 7.83 (dt, 1H, J1= 1.3 Hz, J2 = 7.9 Hz), 
7.9 (t, 1H, J = 1.8 Hz), 8.65 (s, 1H). 
13C NMR (DMSO-d6, 400.13 MHz): δ 48.22 (2C), 49.46 
(2C), 54.74 (1C), 64.42 (1C), 68.57 (2C), 122.72 (1C), 123.69 (1C), 124.67 (1C), 127.58 
(1C), 130.86 (1C), 132.87 (1C), 133.68 (1C), 144.93 (1C). HRMS (ESI
+): m/z [M + H]
+ 
calculated  for  C16H23ClN5O:  336.1586;  found:  336.1586.  HPLC-MS  (MeOH/H2O):  purity 
99.68%. 
 
Binding  affinity  of  compound  15  was  determined  in  a  competitive  binding  assay  by 
measuring displacement of radioactive labeled [
3H]histamine bound to H4R.
169 Membrane 
preparations of insect Sf9 cells expressing hH4R together with G-protein subunits Gαi2 and 
Gβ1γ2 were performed to yield the protein. A similar assay was used to measure the activity 
on hH3R (reference ligand: [
3H]N
α -methylhistamine). 
 
Compound 15 exhibits only weak affinity to hH4R. From three measurements, a mean Ki of 
436 µM (STD: ±137 µM) was determined. Comparable results were found for the activity of 
15 on the H3 receptor (Ki = 466 µM (±209 µM), averaged over four distinct tests). 
Although the flexible alignment of compound 15 and the reference ligand does not directly 
align the central hydrogen bond acceptors, they might still be able to undergo an interaction 
with the same hydrogen bond donor of the receptor binding site according to the alignment 
(Figure 23).  
 
 
Figure 23. Flexible alignment of compound 15 (gold) and the reference JNJ 
7777120 (light blue) computed by a component of the software suite MOE. 
Low activity of compound 15 may be caused by a missing hydrogen bond 
donor in the central part, which is present in the reference ligand (arrow). 	
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The alignment also suggests a possible reason for the weak activity of compound 15: JNJ 
7777120 exhibits a hydrogen bond donor (nitrogen of the indole scaffold) in the center of the 
molecule. Compound 15 does not feature an equivalent atom capable to act as a hydrogen 
bond donor. It has been suggested that this pharmacophoric feature might be important for 
high affinities to hH4R.
167 Introduction of a hydrogen bond donor in the central part of 15 can 
therefore be a possible strategy for structural optimization. Another possibility to improve the 
potency  of  15  by  a  comparably  small  structural  modification  could  be  to  replace  the 
piperazine moiety of 15 with N-methylpiperazine found in many H4 reference compounds. It 
is known that even small changes of the N-methylpiperazine group can lead to a considerable 
decrease of affinity of H4 receptor ligands.
166 
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4 Conclusions and Outlook 
 
This work presents a new method for automated de novo design of ligand candidates. The 
program DOGS was evaluated in both theoretical and practical case studies. 
The main advantage of DOGS over most of the other existing software tools for de novo 
design is its ability to suggest not only new compounds but also reasonable pathways for their 
synthesis. The set of reactions as well as the library of synthesis building blocks can be 
modified by the user to provide flexibility with respect to preferred chemistry and available 
educts.  
Synthesizability of proposed compounds is pivotal for the practical evaluation of de novo 
design tools. It can be argued that lacking ease of synthesis of designed molecules is one of 
the reasons why only around a dozen of all published algorithms for molecular de novo design 
have  been  subjected  to  practical  evaluation.  The  aim  of  this  study  was  to  show  that  an 
enhanced  build-up  strategy  employing  known  chemical  reactions  can  facilitate 
synthesizability  of  designed  molecules,  and  hence  practical  evaluation  of  de  novo  design 
software.  DOGS  was  evaluated  practically  in  two  realistic  case  studies  on  the  design  of 
potential  ligands  for  human  γ-secretase  and  human  histamine  H4  receptor.  In  both  cases, 
compounds selected for testing were readily synthesizable. In addition, synthesis routes could 
be followed up at the bench exactly as suggested by the software. It is clear that this is to 
some  extent  a  consequence  of  the  selection  process  by  human  experts.  One  criterion  for 
compound  selection  was  a  synthesis  route  deemed  simple  and  pursuable.  It  cannot  be 
expected that all synthesis pathways suggested by DOGS will directly work when pursued in 
the  lab.  Nevertheless,  a  large  part  of  designed  compounds  received  high  synthesizability 
scores calculated by the software MOE, which likely is a consequence of the reaction-driven 
compound construction concept of DOGS. 
Synthesized  candidate  ligands  for  γ-secretase  exhibit  biological  activity.  Although  target 
modulation points in the opposite direction as intended, these molecules show affinity to the 
target  and  provide a   valuable  basis  for  further  investigation.  The  molecule  selected  and 
synthesized as a potential ligand for the H4 receptor only exhibits weak activity, probably due 
to a missing pharmacophoric feature in the center of the molecule. 
Besides these practical evaluations, theoretical investigation of DOGS results was performed 
and  revealed  that  the  software  is  capable  of  capturing  a  calculated  biophysical  property 
(logP(o/w)) of reference compounds and reflecting it in the constructed molecules. Notably, 	
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this property is not explicitly accounted for in similarity assessment by the scoring function. 
A large fraction of molecules designed by DOGS are evaluated to be druglike and mostly 
violate less than two of Lipinski’s ‘rule of five’. Again, designed compounds generally reflect 
the  reference  compounds  in  these  properties.  Features  of  proposed  candidate  structures 
depend on characteristics provided by the references. This behavior is intended for de novo 
design,  since  property  profiles  of  molecules  are  thought  to  be  linked  to  their  biological 
activities  and  pharmacokinetic  characteristic.
84  DOGS  designs  originating  from  druglike 
reference compounds have an enhanced chance to be druglike themselves. 
DOGS  introduces  graph  kernel  methods  for  scoring  to  the  field  of  de  novo  design.  The 
employed ISOAK method has proven to be well-suited for the DOGS approach. The reason is 
likely to be found in the concept of ISOAK to compare molecules: it assigns each atom of the 
smaller molecules to one atom of the larger compound. This renders it possible to compare 
molecules significantly differing in size, which is a requirement for the stepwise build-up 
process of the algorithm. Potentially small intermediate products are also scored against the 
complete reference ligand. In addition, the kernel is not restricted to molecular graphs. This 
allowed  for  the  implementation  of  a  reduced  graph  representation  for  molecules,  which 
extends the pool of meaningful results produced by DOGS. As a consequence of the ligand-
based scoring approach, the software can be run with a minimum of available knowledge 
about the target molecule. A single reference compound known to be active on the target is 
sufficient to let the software create ideas for new ligands. This feature is of special merit for 
drug development campaigns for structurally unexplored targets.  
 
For future work, a reduction of the number of duplicate molecules in output lists presents a 
way to speed-up calculations and save computational power. Duplicates with nearly exact 
synthesis pathways represent redundant information and could be avoided without loss of 
important information. A possible remedy to this problem would be to store a list of all 
dummy products already selected to be pursuit in the subsequent reaction step in former 
synthesis pathways. Whenever the current virtual synthesis chooses a dummy product that has 
already  been  selected  before,  the  construction  process  could  be  stopped.  Because  of  the 
deterministic characteristic of the algorithm all subsequent steps would exactly be the same as 
already calculated. One could either delete the current synthesis and proceed with the next 
construction  pathway  or  complement  it  with  the  remaining  part  of  the  pathway  already 
calculated  before  and  store  it.  The  comparison  of  dummy  fragments  could  be  efficiently 
implemented to work on a prefix tree of canonical SMILES
170 representations. 	
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In order to broaden the scope of DOGS and increase flexibility with respect to implementable 
reactions, the algorithm could be extended to process reactions with more than two educts. 
However, one has to keep in mind that this will likely result in increased run times because of 
the higher number of possible educt combinations. 
Detection of isofunctional reactive groups in educts in order to avoid unwanted side reactions 
would be of great potential for improvements of the method. For example, the presence of an 
additional secondary amine in one of the reaction partners of a reductive amination between a 
carbonyl group and a primary amine is prone to lead to unwanted byproducts. Recognition of 
competing reactive substructures could be used to either flag the corresponding intermediate 
product with a warning mark and suggest protection groups or to prohibit the reaction. This 
approach  depends  on  a  careful  definition  of  competing  reactive  substructures  for  every 
reaction.  Although  this  step  only  has  to  be  performed  once  per  reaction  during  its 
implementation, it represents a significant effort and is prone to over-regimentation. A more 
elaborate  way  to  deal  with  competing  reactions  would  be  to  computationally  estimate 
substructure reactivity. It is far too demanding to calculate reactions ab initio by quantum 
mechanical methods. However, quantum mechanical calculations could be used to prioritize 
multiple occurrences of the same reactive group with respect to their reactivity. In fact, this 
has already been introduced to de novo design in the software tool SYNOPSIS
57 for a special 
type of reaction. Notably, the authors concluded that the additional computational costs are 
not justified by the improvements by this approach and excluded it from the final version of 
the software. However, it could be shown that this method works in principle. It will probably 
become of higher practical relevance with increasing computational power in the future. 
Besides  the  potential  advantages  of  ligand-based  de  novo  design  it  must  be  stated  that 
available structural information about the target binding site can be of merit and should be 
incorporated in the design of potential ligands. For this reason, an extension of the DOGS 
approach  towards  receptor-based  scoring  is  expected  to  be  beneficial  for  targets  where 
structural data exist. The success of this effort depends on finding a receptor-based scoring 
function capable of preferring small but promising intermediate products over larger ones 
having less potential to be extended to favorable final solutions. Scoring functions of docking 
tools have the tendency to favor larger ligands exhibiting more atoms to interact with the 
receptor binding site.
171 Normalization of docking scores by the number of heavy atoms could 
offer a simple and self-evident solution. Another critical point of 3D scoring functions is their 
higher computational demand compared to 2D techniques. During a DOGS run a (potentially) 	
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large number of scores needs to be calculated due to the enumeration of complete subspaces 
in each reaction step. A less demanding scoring function could be employed as a filter to 
narrow down the number of molecules subsequently scored by the more expensive 3D scoring 
function to those deemed favorable. 
 
Generating innovative and patentable molecules with biological activity form scratch is an 
appealing, yet demanding goal. Current software solutions to this problem are far away from 
being  ‘click-and-harvest’  applications  that  can  guarantee  to  produce  readily  exploitable 
results. De novo design is still dependent on intervention and support of human expertise. 
Nevertheless, it can be a valuable source of inspiration and new ideas for drug development 
projects. In fact, reports about successful application of respective software tools make it safe 
to say that computational de novo design works.
81,104,114 Incorporating synthesis pathways – as 
presented in this work – can focus de novo design on a more practical standard and adds an 
important level of information to the output. 
The main reason why de novo design has not yet grown out of its role as a pure idea generator 
is our lack of a deeper understanding about interactions taking place between receptors and 
their ligands upon binding, which is expressed in insufficient scoring functions for molecular 
docking. Especially entropic contributions to binding energies and solvent effects are still 
widely ignored. The same holds true for our understanding about chemical similarity between 
small organic molecules. The special problem of the similarity concept in molecular design is 
that in reality similarity is ‘measured’ by a binding cavity, which is different for every target. 
Presence or absence of a structural feature in a ligand might be tolerated by one binding site, 
but leads to significant changes of binding affinity in the next case. A molecular feature that is 
important for one target may be less critical in the context of another one. Target dependency 
of the similarity concept makes it difficult to extract general rules applicable over a wide 
range of different target molecules. 
Broader application of de novo design methods has also been hampered for a long time by a 
lack  of  accessible  and  user-friendly  software  implementations.  In  most  cases,  published 
approaches  remain  in-house  solutions  or  even  never  leave  proof-of-concept  status.  The 
situation has started to change only recently, as today almost every large software suite for 
molecular modeling offers a de novo design module. This can be interpreted as a consequence 
of a growing interest in this approach. 
Regardless of these shortcomings, computer-assisted de novo drug design has become an 
established  instrument  in  the  pharmaceutical  industry  as  well  as  in  academia,  and w i l l  	
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continue  to  give  valuable  impulses  to  drug  design  as  a  complementary  tool  to  other 
computational approaches. 	
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Summary 
 
A new method for computer-based de novo design of drug candidate structures is proposed. 
DOGS  (Design  of  Genuine  Structures)  features  a  ligand-based  strategy  to  suggest  new 
molecular  structures.  The  quality  of  designed  compounds  is  assessed  by  a  graph  kernel 
method  measuring  the  distance  of  designed  molecules  to  a  known  reference  ligand.  Two 
graph representations of molecules (molecular graph and reduced graph) are implemented to 
feature  different  levels  of  abstraction  from  the  molecular  structure.  A  fully  deterministic 
construction procedure explicitly designed to facilitate synthesizability of proposed structures 
is realized: DOGS uses readily available synthesis building blocks and established reaction 
schemes to assemble new molecules. This approach enables the software to propose not only 
the final compounds but also to give suggestions for synthesis routes to generate them at the 
bench. The set of synthesis schemes comprises about 83 chemical reactions. Special focus 
was put on ring closure reactions forming drug-like substructures. The library of building 
blocks consists of ~25,000 molecules readily available from a commercial vendor with a 
molecular mass between 30 and 300 Da. 
DOGS builds up new structures in a stepwise process. Each virtual synthesis step adds a 
fragment  to  the  growing  molecule  until  a  stop  criterion  (molecular  mass  or  number  of 
synthesis steps) is fulfilled. 
 
In a theoretical evaluation, a set of ~1,800 molecules proposed by DOGS is analyzed for 
critical properties of de novo designed compounds. The software is able to suggest drug-like 
molecules  (79%  violate  less  than  two  of  Lipinski’s  ‘rule  of  five’).  In  addition,  a  trained 
classifier for drug-likeness assigns a score >0.8 to 51% of the designed molecules (with 1.0 
being the top score). In addition, most of the DOGS molecules are deemed to be highly 
synthesizable by a retrosynthesis descriptor (77% of molecules score in the top 10% of the 
decriptor’s value range). Calculated logP(o/w) values of constructed molecules resemble a 
unimodal  distribution  centered  close  to  the  mean  of  logP(o/w)  values  calculated  for  the 
reference compounds. 
A  structural  analysis  of  selected  designs  reveals  that  DOGS  is  capable  of  constructing 
molecules reflecting the overall topological arrangement of pharmacophoric features found in 
the reference ligands. At the same time, the DOGS designs represent innovative compounds 
being structurally distinct from the references. Synthesis routes for these examples are short 	
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and  seem  feasible  in  most  cases.  Some  reaction  steps  might  need  modification  by  using 
protecting groups to avoid unwanted side reactions. 
Plausible bioisosters for known privileged fragments addressing the S1 pocket of trypsin were 
proposed by DOGS in a case study. Some of them can be found in known trypsin inhibitors as 
S1-adressing side chains. 
 
The software was also tested practically in two realistic drug design scenarios. DOGS was 
applied to design ligands for human γ-secretase and human histamine receptor subtype 4 
(hH4R). Two selected designs for γ-secretase were readily synthesizable as suggested by the 
software in one-step reactions. Both compounds modulate the activity of the target molecule, 
although the effect differs from the one suggested as a potential treatment Alzheimer patients. 
These structures can serve as starting points for structural optimization. In a second case 
study, a ligand candidate selected for hH4R could again be synthesized exactly following the 
three-step synthesis plan suggested by DOGS. This compound showed only low activity on 
the  target  structure.  Nevertheless,  these  examples  represent  promising  initial  results.  The 
concept of DOGS could proof to deliver not only synthesizable compounds but also pursuable 
synthesis  plans.  Future  practical  applications  of  the  software  will  help  to  gain  a  more 
comprehensive  impression  of  the  method´s  power  to  contribute  to  the  development  of 
bioactive compounds. 
 
 	
 ﾠ 78 
Zusammenfassung 
 
Das  Ziel  des  computergestützten  de  novo  Designs  ist  der  Neuentwurf  biologisch  aktiver 
Verbindungen, welche als Vorläufer für mögliche Wirkstoffe dienen können. Die zentrale 
Idee  ist  es,  molekulare  Fragmente  neu  zusammen  zu  setzen,  um  maßgeschneiderte 
Modulatoren für ein gegebenes Zielmolekül (zumeist ein Protein) zu erhalten. Der Fokus von 
de novo Design liegt dabei auf der Innovation und Neuartigkeit der entworfenen Substanzen. 
Dies  unterscheidet  die  Methode  grundsätzlich  vom  virtuellen  Screening  (VS),  bei  dem 
Sammlungen  bereits  existierender  und  beziehbarer  Moleküle  nach  potentiellen 
Wirkstoffkandidaten durchsucht werden. 
Die  ersten  veröffentlichten  de  novo  Design  Ansätze  konzentrierten  sich  darauf,  neue 
potentielle  Liganden  direkt  in  der  Bindetasche  zu  konstruieren.  Dies  geschieht  unter  der 
Maximierung  von  sterischer  Paßform  und  unter  Berücksichtigung  von  polaren  und 
elektrostatischen Interaktionsmöglichkeiten mit der Rezeptortasche. Dieser rezeptorbasierte 
Ansatz  wurden  bald  durch  ligandenbasierte  Methoden  ergänzt.  Hierbei  zielt  der  Entwurf 
neuer  Moleküle  auf  möglichst  hohe  Ähnlichkeit  zu  bereits  bekannten  Liganden  des 
Zielmoleküls a b .  Nach  dem  zentralen  „Ähnlichkeitsprinzip“  sollen  ähnliche  Moleküle 
vergleichbare  Eigenschaften  aufweisen.  Der  Vorteil  von  ligandenbasierten  Methoden  im 
Vergleich  zu  rezeptorbasierten  Ansätzen  liegt  darin,  dass  sie  keine  Kenntnis  über  die 
räumliche Struktur der Bindetasche voraussetzen, welche für eine Vielzahl pharmazeutisch 
relevanter Zielmoleküle tatsächlich nicht bekannt ist. 
Seit den Anfängen des computergestützten de novo Design kranken die Methoden daran, dass 
entworfene Moleküle zwar als potentiell interessant eingestuft werden, aber oft nur schlecht 
synthetisch zugänglich oder sogar chemisch instabil sind. Neusynthesen sind im Allgemeinen 
deutlich  teuerer  und  aufwendiger  als  der  Bezug f e r tiger  Substanzen  von  kommerziellen 
Anbietern oder aus dem eigenen Bestand. Aus diesem Grund sind bisher nur vergleichsweise 
wenige  der  beschriebenen  Algorithmen  zum  de  novo  Design  überhaupt  einer  praktischen 
Evaluation  unterzogen  worden,  in  der  vorgeschlagene  Moleküle  synthetisiert  und  getestet 
wurden.  Trotzdem  ist  eine  Reihe  erfolgreicher  Anwendungen  von  entsprechenden 
Programmen publiziert, und de novo Design kann als etablierte Methode angesehen werden. 
 
Ziel dieser Arbeit ist die Entwicklung einer Methode zum computergestützten de novo Design 
(DOGS, Design Of Genuine Structures). Der Fokus von DOGS liegt darauf, Moleküle zu 	
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entwerfen, die eine gute Zugänglichkeit durch chemische Synthese aufweisen. Um dies zu 
erreichen, greift die Software auf kommerziell verfügbare Synthesenbausteine und etablierte 
chemische  Reaktionen  zum  Aufbau  neuer  Moleküle  zurück.  Dies  soll  zum  einen  die 
Wahrscheinlichkeit  der  guten  Synthetisierbarkeit  der  aufgebauten  Moleküle  erhöhen,  zum 
anderen  aber  den  Computer  in  die  Lage  versetzen,  unmittelbar  Vorschläge  für  eine 
Synthesestrategie zu generieren. Ziel ist die Erhöhnung der Akzeptanz der Ergebnisse und die 
Erleichterung der praktischen Umsetzung. 
 
Die  Bibliothek  der  Synthesebausteine  besteht  aus  etwa  25.000  physikalisch  verfügbaren 
Moleküle  mit  einer  molekularen  Masse  zwischen  30  und  300  Da.  Eine  Reihe  von 
Filterkriterien  wurde  verwendet,  um  unerwünschter  Verbindungen  zu  entfernen  sowie 
Ladungs- und Protonierungszustände zu standardisieren. Zusätzlich wurde eine Sammlung 
von Präparations-Reaktionen angewendet, um weitere funktionelle Gruppen in die virtuellen 
Synthesebausteine einzuführen. Dies dient der Aktivierung von reaktiven Gruppen und damit 
ihrer späteren Umsetzung durch die Reaktionen zur Kopplung der Bausteine. Abschließend 
wurde  jeder  Baustein  auf  das  Vorhandensein  aller  durch  die  Reaktionen  festgelegten 
reaktiven Gruppen überprüft und die entsprechende Information zusammen mit dem Baustein 
in einer MySQL Datenbank gespeichert. 
Die  Reaktionssammlung  umfaßt  83  Reaktionen  und  wurde  durch  eine  Literaturrecherche 
zusammengestellt.  Insbesondere  wurden  solche  Reaktionen  gewählt,  die  Substrukturen 
erzeugen, welche häufig in biologisch aktiven und wirkstoffartigen Molekülen vorkommen. 
Aus  diesem  Grund  befindet  sich  ein  großer  Anteil  Ringschlußreaktionen  in  der 
Reaktionsbibliothek.  Weitere  Kriterien  zur  Auswahl  der  Reaktionen  umfaßten  hohe 
beschriebene  Ausbeuten,  Vermeidung  toxischer  Reagenzien  und  Katalysatoren  sowie 
einfache praktische Durchführbarkeit. 
DOGS verwendet eine ligandenbasierte Strategie zur Bewertung der entworfenen Moleküle. 
Eine Kernfunktion vergleicht die erzeugten Moleküle mit einem Referenzliganden anhand 
ihrer  Graphenrepräsentationen.  Die  berechnete  Distanz  zum  Referenzliganden  wird  als 
Gütemaß  verwendet.  Im  Rahmen  der  Arbeit  kommen  zwei  verschiedene 
Graphenrepräsentationen zum Einsatz. Der molekulare Graph entspricht der topologischen 
Struktur einer zweidimensionalen Moleküldarstellung. Jedes Atom wird in einen Knoten und 
jede Bindung in eine Kante des Graphen übersetzt. Im Gegensatz dazu stellt der reduzierte 
Graph  eine  stärkere  Abstraktion  von  der  Molekülstruktur  dar.  Bestimmte  Substrukturen 
bestehend  aus  mehreren  Atomen  (vor  allem  Ringsysteme,  lipophile  Bereiche)  werden  zu 	
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einem  einzelnen  Koten  zusammengefaßt.  Der  reduzierte  Graph  stellt  damit  nur  noch  die 
topologische  Anordnung  bestimmter  Substrukturen  des  Moleküls  dar.  Der  Anwender  legt 
fest, welche der beiden Moleküldarstellung in einem Konstruktionslauf Verwendung findet. 
Neue Moleküle werden von DOGS schrittweise aufgebaut, wobei pro Erweiterungsschritt je 
ein  weiterer  Baustein  an  das  wachsende  Molekül  angefügt  wird.  Das  Startfragment  einer 
virtuellen Synthese wird aus allen Fragmenten gemäß seiner Güte ausgewählt. Dazu wird die 
gesamte Fragmentbibliothek zunächst wie beschrieben mit dem Referenzliganden verglichen. 
Die  Synthesebausteine  mit  der  höchsten  Güte  werden  als  Startfragmente  verwendet.  Ein 
Erweiterungsschritt  besteht  aus  zwei  Unterschritten.  Zunächst  wird  bestimmt,  welche  der 
anwendbaren Reaktionen das größte Potential bietet. Dazu werden alle reaktiven Gruppen des 
zu  erweiternden  Zwischenprodukts  mit  passenden  Reaktionen  und  minimalen  Dummy-
Fragmenten als Edukte abreagiert. Das Konzept der minimalen Dummy-Fragmente wird in 
DOGS eingeführt, um die mindestens zu erwartende strukturelle Veränderung abzuschätzen, 
die  eine  Reaktion  verursacht.  Die  Dummy-Fragmente  werden  durch  die  Definition  der 
Reaktion festgelegt und weisen ausschließlich jene strukturellen Elemente auf, die für die 
Durchführung der Reaktion unbedingt notwendig sind. Alle Dummy-Produkte, die aus diesen 
Pseudoreaktionsschritten  hervorgehen,  werden  mittels  der  Gütefunktion  bewertet.  Die 
Reaktion, welche das beste Dummy-Produkt liefert, wird im zweiten Unterschritt verwendet. 
In diesem zweiten Schritt wird die Reaktion mit dem zu erweiternden Zwischenprodukt und 
allen Synthesefragmenten aus der Bibliothek, welche die komplementäre reaktive Substruktur 
aufweisen, durchgeführt. Aus allen entstehenden Produkten wird abschließend jenes mit der 
höchsten Güte als neues Zwischenprodukt gewählt, welches im nächsten Erweiterungsschritt 
bearbeitet  wird.  Dies  wiederholt  sich,  bis  das  Molekül  entweder  eine  Mindestmasse 
überschritten  und  ein  Erweiterungsschritt  mit  verschlechternder  Güte  durchgeführt  wurde 
oder das wachsende Molekül eine maximale molekulare Masse überschreitet. Anschließend 
wird ein neues Startfragment gewählt und die nächste virtuelle Synthese beginnt. Eine vom 
Benutzer bestimmbare Anzahl von Startfragmenten wird so abgearbeitet. Alle Schritte des 
Aufbauprozesses sind deterministisch. 
 
DOGS wurde zunächst in einer Reihe von theoretischen Untersuchungen evaluiert. Neben den 
Faktoren,  welche  zwangsläufig  Einfluß  auf  die  Laufzeit  haben  (Anzahl  Fragmente  und 
Reaktionen, gewählte Anzahl zu bearbeitender Startfragmente, Größe des Referenzmoleküls), 
ist  vor  allem  die  Parametrisierung  der  Gütefunktion  für  die  Dauer  eines  DOGS-Laufes 
verantwortlich. In einem Testszenario erzeugte ein durchschnittlicher DOGS-Lauf mit 200 	
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Startfragmenten  und  der  Standardparametrisierung  des  molekularen  (reduzierten) 
Molekülgraphen  etwa  180  (240)  unterschiedliche  Molekülstrukturen  in  11  (10)  Stunden. 
Diese  basieren  in  beiden  Fällen  auf  ca.  70  unterschiedlichen  molekularen  Grundgerüsten 
(Scaffolds). Eine nähere Untersuchung der Ähnlichkeiten zwischen Referenz-Scaffold und 
von  DOGS  erzeugten  Scaffolds  zeigte,  dass  sich  die  beiden  Graphenrepräsentationen  in 
diesem  Punkt  für  das  gewählte  Ähnlichkeitsmaß  nur  unwesentlich  differieren.  Die 
durchschnittliche Distanz der erzeugten Scaffolds zur Referenz im gewählten Deskriptorraum 
unterscheidet  sich  für  beide  Moleküldarstellungen  kaum.  Ein  Vergleich  auf  struktureller 
Ebene zeigte jedoch, dass sich zwischen den Graphenrepräsentationen nur geringe bis mäßige 
Überschneidungen in den erzeugten Scaffolds ergeben. Die beiden Graphenrepräsentationen 
sind  somit  komplementär  und  ergeben  zusammen  eine  reichhaltigere  Sammlung  an 
entworfenen Scaffolds als jede für sich. 
DOGS  sollte  in  der  Lage  sein,  wirkstoffartige  Moleküle  zu  generieren,  sofern  das 
Referenzmolekül ebenfalls wirkstoffartig ist. Um dies zu überprüfen, wurden die erzeugten 
Moleküle  aus  insgesamt  zehn  DOGS-Läufen  basierend  auf  fünf  verschiedenen  Trypsin-
Inhibitoren hinsichtlich dieser Eigenschaft untersucht. Ein Großteil (79%) der entworfenen 
Moleküle verletzt weniger als zwei von Lipinkis „Rule of 5“ Kriterien für bioverfügbare 
Moleküle. Weiterhin beurteilt ein Klassifizierer für Wirkstoffartigkeit 51% der Moleküle mit 
einem Wert >0,8, wobei 1,0 dem Höchstwert entspricht. Die übrigen 49% der Werte verteilen 
sich relativ homogen über die Bandbreite möglicher Einschätzungen, mit der Ausnahme, dass 
auch  ein  deutlicher  Anteil  als  nicht  wirkstoffartig  eingestuft  wird.  Dabei  ist  zu 
berücksichtigen,  dass  auch  zwei  der  Referenzliganden  als  wirkstoff-untypisch  bewertet 
werden.  Die  entworfenen  Moleküle  folgen  weiterhin  in  der  Verteilung  ihrer  berechneten 
logP(o/w) Werte der Verteilung dieser Eigenschaft in den Referenzmolekülen. Generell zeigt 
diese Analyse, dass DOGS in der Lage ist Eigenschaften der Referenzen in die entworfenen 
Moleküle  zu  übertragen,  die  nicht  explizit  in  die  Ähnlichkeitsbewertung  während  der 
Konstruktion eingehen. 
Die Synthetisierbarkeit der von DOGS vorgeschlagenen Moleküle wird für einen Großteil als 
sehr  gut  bewertet  (77%  aller  Moleküle  liegen  in  den  oberen  10%  der  Werteskala).  Zur 
Bewertung dieser Eigenschaft wurde ein deskriptorbasiertes Verfahren zur retrosynthetischen 
Zerlegbarkeit  von  Molekülen  herangezogen.  Der  verbleibende  Anteil  verteilt  sich  auf  das 
obere Mittelfeld des möglichen Wertebereiches. Insgesamt folgt auch hier die Verteilung der 
DOGS-Moleküle der Werteverteilung der Referenzen. Die reaktionsgetriebene Verknüpfung 	
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von verfügbaren Ausgangsmaterialien resultiert in einer ausgesprochen positiven Bewertung 
der Synthetisierbarkeit der so konstruierten Moleküle. 
Die  visuelle  Bewertung  von  ausgewählten  DOGS  Entwürfe  für  drei  unterschiedliche 
Zielmoleküle (Trypsin, Östrogen Rezeptor, TGF-β1 Rezeptor) zeigte, dass das Programm in 
der Lage ist, die räumliche Anordnung von potentiellen Interaktionszentren der Referenzen in 
die  konstruierten  Moleküle  zu  übertragen.  Dabei  unterscheiden  sich  die  vorgeschlagenen 
Moleküle  in  unterschiedlichem  Maße  strukturell  von  der  jeweiligen  Referenz.  Die 
zugehörigen  Reaktionswege  sind  kurz  (ein  bis  zwei  Syntheseschritte)  und  erscheinen 
plausibel.  Bei  einigen  Schritten  kann  der  Einsatz  von  Schutzgruppen  zur  Vermeidung 
konkurrierender  Nebenreaktionen  notwendig  sein.  Weiterhin  wurden  die  besten  200  für 
Trypsin  entworfenen  DOGS-Moleküle  auf  vorgeschlagene  Bioisostere  für  die S 1 -Tasche-
adressierenden  Seitenketten  der  Referenzen  untersucht.  Unter  den  11  vorgeschlagenen 
Seitenketten  befindet  sich  unter  anderem  auch  die  Seitenkette  von  Lysin,  welche  ein 
natürlicher Ligand der S1-Tasche ist und sich von den Referenzmotiven abhebt. Zwei weitere 
vorgeschlagene  Bioisostere  sind  in  bekannten  Trypsin-Inhibitoren  als  S1-adressierende 
Seitenkette zu finden. Die meisten der vorgeschlagenen Seitenketten sind positiv ionisierbar 
und damit in der Lage, eine für die Bindung entscheidende ionische Wechselwirkung mit dem 
Rezeptor in der S1-Tasche einzugehen. 
Schließlich  wurde  DOGS  in  zwei  realistischen  Szenarien  zur  Identifizierung  neuartiger 
bioaktiver Moleküle eingesetzt und praktisch evaluiert. Für die humane γ-Sekretase wurden 
aus  acht  Läufen  für  vier  verschiedene  Referenz-Moleküle  zwei  potentielle  Liganden  zur 
Synthese  ausgewählt.  Beide  Verbindungen  ließen  sich  nach  dem  vom  Programm 
vorgeschlagenen  Syntheseweg  herstellen.  Weiterhin  zeigen  beide  Liganden  einen 
biologischen  Effekt  am  Zielmolekül  und  modulieren  die  Aktivität  der  γ-Sekretase.  Die 
Modulation  entspricht  dabei  allerdings  nicht  der  ursprünglich  für  therapeutische  Zwecke 
vorgeschlagenen  Art  und  Weise.  Die  Verbindungen  können  als  Startpunkt  weiterer 
struktureller Optimierungen dienen.  
In einer zweiten praktischen Studie mit dem Ziel des Ligandenentwurfs für den humanen 
Histaminrezeptor  Typ  4  wurde  aus  der  Menge  der  computergenerierten  Vorschläge  eine 
Verbindung  zur  Synthese  und  Testung  ausgewählt.  Die  dreistufige  Synthese  konnte  wie 
vorgeschlagen nachvollzogen werden. Der Ligand zeigt mit einem Ki von 436 µM jedoch nur 
sehr  schwache  Aktivität.  Grund  dafür  könnte  ein  fehlender  Wasserstoffbrückendonor  im 
zentralen  Teil  des  Liganden  sein,  der  in  anderen  Studien  als  Teil  des  Pharmakophors 
angenommen wurde. 	
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Mit  DOGS  wurde  ein  neues  Werkzeug  zum  de  novo  Design  wirkstoffartiger  Moleküle 
vorgeschlagen.  DOGS  gehört  zu  den  wenigen  Programmen  dieser  Art,  welche  einer 
praktischen  Evaluierung  unterzogen  wurden.  Die  Ergebnisse  der  retrospektiven  und 
prospektiven Auswertung zeigen das Potential des Ansatzes auf, Vorschläge von praktischer 
Relevanz zu generieren. Das Konzept zum Molekülaufbau von DOGS hat gezeigt, dass es 
nicht nur synthetisierbare Strukturen hervorbringt, sondern zusätzlich auch nachvollziehbare 
praktikable Vorschläge für deren Synthese liefern kann. Dies ist ein essentieller Vorteil im 
praktischen Einsatz gegenüber vielen bisher beschriebenen Ansätzen zum de novo Design. 
Zukünftige  Verbesserungen  in  unserem  Verständnis  von  molekularer  Ähnlichkeit  und 
Liganden-Rezeptor-Wechselwirkungen können problemlos in Form neuer Gütefunktionen in 
das Konzept von DOGS eingebunden werden. 
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Supplement 
 
Each coupling and preprocessing reaction is given by the following specifications: 
•  Reaction-MQL expression, 
•  Schematic structural representation,  
•  Minimal  structure  of  educt(s)  encoded  as  SMILES,  also  representing  the  dummy 
fragment used during construction.  
Please  note  that  the  schematic  structural  representation  not  necessarily  corresponds 
completely  to  the  minimal  dummy  structure  given.  Schematic  representations  serve  for 
visualization only. 
 
Coupling Reactions 
 
1.  c$1:c4[allHydrogens=1]:c(-C6[allHydrogens=2]-C7[allHydrogens=2]-N2-C3(=O5)-C):c:c:c$:1 >> 
Bischler-Napieralski >> C6-C7-N2=C3-c4   
 
 
 
c1cc(CCNC(=O)C)ccc1 
 
2.  c$1:c4[allHydrogens=1]:c(-C6(-O8[allHydrogens=1])-C7[allHydrogens=2]-N2-C3(=O5)-C):c:c:c$:1 >> 
Pictet-Gams >> C6=C7-N2=C3-c4   
 
 
 
c1cc(C(O)CNC(=O)C)ccc1 
 
3.  c2[allHydrogens=1]:c(-C5[sp3 & !ring]-C6[sp3 & !ring]-N7[allHydrogens=2 & charge=0]):c[!bound(-H)] 
++ C3[allHydrogens=1](=O4)-C >> Pictet-Spengler (charge 1)  >> C5-C6-N7-C3-c2   
 
 
 
c1cc(CCN)c(C)cc1    +    CC(=O) 
   
HN
R
O N
R
HN
R
O
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N
R
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R
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c2[allHydrogens=1]:c(-C5[sp3 & !ring]-C6[sp3 & !ring]-N7[allHydrogens=3 & charge=1]):c[!bound(-H)] 
++ C3[allHydrogens=1](=O4)-C >> Pictet-Spengler (charge 2)  >> C5-C6-N7-C3-c2 
 
 
 
c1cc(CC[NH3+])c(C)cc1    +     CC(=O) 
 
4.  c$1:c:c:c(-N3[allHydrogens=2]):c2[allHydrogens=1]:c$:1 ++ c-C4(=O5)-C6-*7[Cl|Br] >> Bischler Indole 
>> N3-C4=C6-C2 
 
 
 
c1c(N)cccc1     +    c1c(C(=O)CBr)cccc1 
 
5.  c$1:c[allHydrogens=1]:c(-N7[allHydrogens=2]):c(-N8[bound(-H)]):c[allHydrogens=1]:c$:1 ++ C3(=O4)(-
O5[allHydrogens=1])-C >> Benzimidazol (charge 1)  >> N7=C3-N8 
 
 
c1cccc(N)c1NC    +    CC(=O)O 
 
c$1:c[allHydrogens=1]:c(-N7[allHydrogens=2]):c(-N8[bound(-H)]):c[allHydrogens=1]:c$:1 ++ C3(=O4)(-
O5[charge=-1])-C >> Benzimidazol (charge 2)  >> N7=C3-N8 
 
 
 
c1cccc(N)c1NC    +    CC(=O)[O-] 
 
6.  C-C4(-*5[Cl|Br])-C6(=O7)-C >> Aminothiazol  >> C4$8-S-C(-N)=N-C6$=8   
 
 
 
CC(=O)C(Br)C 
 
7.  c$1:c[allHydrogens=1]:c(-O7[allHydrogens=1]):c(-N8[allHydrogens=2]):c[allHydrogens=1]:c$:1 ++ 
C3(=O4)(-O5[allHydrogens=1])-C >> Benzoxazol  (charge 1)   >> O7-C3=N8 
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c1ccc(N)c(O)c1    +    CC(=O)O 
 
c$1:c[allHydrogens=1]:c(-O7[allHydrogens=1]):c(-N8[allHydrogens=2]):c[allHydrogens=1]:c$:1 ++ 
C3(=O4)(-O5[charge=-1])-C >> Benzoxazol (charge 2)   >> O7-C3=N8 
 
 
 
c1ccc(N)c(O)c1    +    CC(=O)[O-] 
 
8.  c$1:c:c(-S7[allHydrogens=1]):c(-N8[allHydrogens=2]):c:c$:1 ++ C3[allHydrogens=1](=O4)-c >> 
Benzothiazol  >> S7-C3=N8 
 
 
 
 
c1ccc(N)c(S)c1    +    c1cc(C(=O))ccc1 
 
9.  c$1:c:c(-O7[allHydrogens=1]):c(-C8[allHydrogens=1]=O9):c:c$:1 ++ *5[Cl|Br]-C3[allHydrogens=2]-
C(=O)-C >> Rap-Stoermer >> O7-C3=C8   
 
 
 
c1ccc(O)c(C(=O))c1    +    CC(=O)CCl 
 
 
10.  c$1:c:c(-N1[allHydrogens=2]):c(-C2(=O)-O4[allHydrogens=1]):c:c$:1 >> Niementowski (charge 1) >> C2-
N-C=N1    
 
 
 
c1ccc(N)c(C(=O)O)c1 
 
c$1:c:c(-N1[allHydrogens=2]):c(-C2(=O)-O4[charge=-1]):c:c$:1 >> classical Niementowski (charge 2) >> 
C2-N-C=N1 
 
 
 
c1ccc(N)c(C(=O)[O-])c1 
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11.  c[allHydrogens=1]$1:c[allHydrogens=1]:c(-N2[allHydrogens=2]):c(-C5(=O)-
O4[allHydrogens=1]):c[allHydrogens=1]:c[allHydrogens=1]$:1 ++ C-N3[allHydrogens=2 & charge=0] >> 
Quinazolinone (Ladung 1)  >> N2=C-N3-C5   
 
 
 
c1ccc(N)c(C(=O)O)c1    +    CN 
 
c[allHydrogens=1]$1:c[allHydrogens=1]:c(-N2[allHydrogens=2]):c(-C5(=O)-O4[charge=-
1]):c[allHydrogens=1]:c[allHydrogens=1]$:1 ++ C-N3[allHydrogens=2 & charge=0] >> Quinazolinone 
(Ladung 2)  >> N2=C-N3-C5   
 
 
 
c1ccc(N)c(C(=O)[O-])c1    +    CN 
 
c[allHydrogens=1]$1:c[allHydrogens=1]:c(-N2[allHydrogens=2]):c(-C5(=O)-
O4[allHydrogens=1]):c[allHydrogens=1]:c[allHydrogens=1]$:1 ++ C-N3[allHydrogens=3 & charge=1] >> 
Quinazolinone (Ladung 3)  >> N2=C-N3-C5 
 
 
 
c1ccc(N)c(C(=O)O)c1    +    C[NH3+] 
 
c[allHydrogens=1]$1:c[allHydrogens=1]:c(-N2[allHydrogens=2]):c(-C5(=O)-O4[charge=-
1]):c[allHydrogens=1]:c[allHydrogens=1]$:1 ++ C-N3[allHydrogens=3 & charge=1] >> Quinazolinone 
(Ladung 4)  >> N2=C-N3-C5   
 
 
 
c1ccc(N)c(C(=O)[O-])c1    +    C[NH3+] 
 
12.  c$1:c:c(-N-C(=O)-C1[allHydrogens=2 & !ring]-C2[!ring](=O3)-C):c4:c:c$:1 >> Chinolin-2-one intramol.  
>> C1=C2-c4   
 
 
 
c1cc(NC(=O)CC(=O)C)ccc1 
 
13.  C-C1#N2 >> Tetrazol  >> C1$1=N2-N[charge=-1]-N=N$-1   
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CC#N 
 
14.  C-N1[allHydrogens=2 & charge=0] ++ C-C2[allHydrogens=1](-C3(=O4)-C)-O5[allHydrogens=1] >> 
Tetrahydro-Indole (charge 1)  >> C$1-C-C$2-N1-C3=C2-C$=2-C-C$-1 
 
 
 
CN    +    CC(=O)C(O)C 
 
C-N1[allHydrogens=3 & charge=1] ++ C-C2[allHydrogens=1](-C3(=O4)-C)-O5[allHydrogens=1] >> 
Tetrahydro-Indole (charge 2)  >> C$1-C-C$2-N1-C3=C2-C$=2-C-C$-1   
 
 
 
C[NH3+]    +    CC(=O)C(O)C 
 
15.  C1-C2[!ring](=O10)-C3[allHydrogens=2]-C4(=O11)-C5 >> 3-nitrile pyridine (symmetry 1)  >> N$1=C(-
O)-C(-C#N)=C2(-C1)-C3=C4$-1(-C5) 
 
 
 
CC(=O)CC(=O)C   
 
C1-C2[!ring](=O10)-C3[allHydrogens=2]-C4(=O11)-C5 >> 3-nitrile pyridine (symmetry 2)  >> N$1=C(-
O)-C(-C#N)=C2(-C5)-C3=C4$-1(-C1) CC(=O)CC(=O)C 
 
 
 
CC(=O)CC(=O)C 
 
16.  c-C1#N2[allHydrogens=0] ++ N3[allHydrogens=2]-N6[allHydrogens=1]-C4(=O5)-c >> Triazole  >> 
C1$8=N3-N6-C4=N2$-8 
 
 
 
c1ccccc1C#N    +    NNC(=O)c1ccccc1 
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17.  C1[sp3]-*2[Cl|Br|I] ++ C3[allHydrogens=1]#C4-C >> Huisgen 1-3 dipolar (azid in_situ)  >> C1-N$1-N=N-
C4=C3[bound(-H)]$-1   
 
 
 
CCl    +    CC#C 
 
18.  C1[!aromatic]=C2[!aromatic]-C3[!aromatic]=C4[!aromatic] ++ C5[!aromatic]=C6[!aromatic] >> Diels-
Alder (symmetry 1)  >> C1$1-C2=C3-C4-C5-C6$-1   
 
 
 
C=CC=C    +    C=C 
 
C1[!aromatic]=C2[!aromatic]-C3[!aromatic]=C4[!aromatic] ++ C5[!aromatic]=C6[!aromatic]>> Diels-
Alder (Symmetrie 2)  >> C1$1-C2=C3-C4-C6-C5$-1    
 
 
 
C=CC=C    +    C=C 
 
19.  C1[!aromatic]=C2[!aromatic & !ring]-C3[!aromatic]=C4[!aromatic] ++ C5#C6 >> Diels-Alder Alkine 
(symmetry 1)  >> C1[!aromatic&!sp2]$1-C2[!aromatic]=C3[!aromatic]-C4[!aromatic&!sp2]-C5=C6$-1 
 
 
 
C=CC=C    +    C#C 
 
C1[!aromatic]=C2[!aromatic]-C3[!aromatic]=C4[!aromatic] ++ C5#C6 >> Diels-Alder Alkine (symmetry 
2)  >> C1[!aromatic&!sp2]$1-C2[!aromatic]=C3[!aromatic]-C4[!aromatic&!sp2]-C6=C5$-1    
 
 
 
C=CC=C    +    C#C 
 
20.  c(-O1[allHydrogens=1]):c(-C(=O)-C2[allHydrogens=3]) ++ C[sp3]$1-C3(=O4)-C[sp3]-C[sp3]-N-C[sp3]$-
1 >> Spiro-piperidine  >> O1-C3-C2   
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c1cc(C(=O)C)c(O)cc1    +    C1C(=O)CCNC1 
 
21.  C-C1[!ring](=O6)-C2-C3(=O7)-C ++ C-N4[allHydrogens=1]-N5[allHydrogens=2] >> Pyrazole (symmetry 
1)  >> C1$1-N4-N5=C3-C2$=1    
 
 
 
CC(=O)CC(=O)C    +    NNC 
C-C1[!ring](=O6)-C2-C3(=O7)-C ++ C-N4[allHydrogens=1]-N5[allHydrogens=2] >> Pyrazol (symmetry 
2)  >> C1$1-N5-N4=C3-C2$=1   
 
 
 
CC(=O)CC(=O)C    +    NNC 
 
22.  C-C1(=O5)-c:c-C2(=O6)-O7[allHydrogens=1] ++ C[!bound(=O) & !bound (=S)]-N3[allHydrogens=1]-
N4[allHydrogens=2] >> Phthalazinone (charge 1)  >> C2-N3-N4=C1   
 
 
 
c1c(C(=O)O)c(C(=O)C)ccc1    +    NNC 
 
 
C-C1(=O5)-c:c-C2(=O6)-O7[charge=-1] ++ C[!bound(=O) & !bound (=S)]-N3[allHydrogens=1]-
N4[allHydrogens=2] >> Phthalazinone (charge 2) >> C2-N3-N4=C1   
 
 
c1c(C(=O)[O-])c(C(=O)C)ccc1    +    NNC 
 
23.  C-C1[!ring](=O7)-C4[!aromatic & bound(-H)]-C5[!aromatic & bound(-H)]-C2(=O6)-C ++ C[!bound(=O)]-
N3[allHydrogens=2 & charge=0] >> Paal-Knorr pyrrole (charge 1)  >> C1$1-N3-C2=C5-C4$=1 
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CC(=O)CCC(=O)C    +    CN 
 
C-C1[!ring](=O7)-C4[!aromatic & bound(-H)]-C5[!aromatic & bound(-H)]-C2(=O6)-C ++ C[!bound(=O)]-
N3[charge=1 & allHydrogens=3] >> Paal-Knorr pyrrole (charge 2)  >> C1$1-N3-C2=C5-C4$=1 
 
 
 
CC(=O)CCC(=O)C    +    C[NH3+] 
 
24.  c-C1(=O4)-C2(=O5)-c ++ C3[allHydrogens=1](=O6)-c$1:c:c:c:c:c$:1 >> Triaryl-imidazol (1,2 diketone) 
>> C1$1-N-C3=N-C2$=1   
 
 
 
c1ccccc1C(=O)C(=O)c1ccccc1    +    c1ccc(C(=O))cc1 
 
25.  c-C1(=O4)-C2(-O5[allHydrogens=1])-c ++ C3[allHydrogens=1](=O6)-c$1:c:c:c:c:c$:1 >> Triarylimidazol 
(alpha hydroxy-ketone) >> C1$1-N-C3=N-C2$=1   
 
 
 
c1ccccc1C(O)C(=O)c1ccccc1    +    c1ccc(C(=O))cc1 
 
26.  c$1:c4[allHydrogens=1]:c(-N5[allHydrogens=1]-N6[allHydrogens=2]):c:c:c$:1 ++ C-C1(=O2)-
C3[allHydrogens=2]-C >> Fischer indole >> N5-C1=C3-c4   
 
 
 
c1ccc(NN)cc1    +    CC(=O)CC 
 
27.  c$1:c(-C4[allHydrogens=1](=O7)):c(-N5[allHydrogens=2]):c:c:c$:1 ++ C-C1(=O2)-C3[allHydrogens=2]-C 
>> Friedlaender chinoline >> N5=C1-C3=C4   
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c1cc(C=O)c(N)cc1    +    CC(=O)CC 
 
28.  c$1:c1[allHydrogens=1]:c(-O2[allHydrogens=1]):c:c:c$:1 ++ C-C3(=O4)-C5[allHydrogens=2 & !ring]-
C6(=O)-O7-C[allHydrogens=2]-C[allHydrogens=3] >> Pechmann coumarine >> c1-C3=C5-C6-O2 
 
 
 
c1cc(O)ccc1    +    CC(=O)CC(=O)OCC 
 
29.  c$1:c(-O1[allHydrogens=1]):c2(-I5):c:c:c$:1 ++ C3[allHydrogens=1]#C4-C >> Benzofuran  >> O1-
C4=C3-c2   
 
 
 
c1cc(O)c(I)cc1    +    CC#C 
 
30.  C-C1(=O2)-C3[bound(-H)](-Br4) >> Imidazol-Acetamid >> C1$1=C3-N-C(-N-C(=O)-C)=N$-1 
 
 
 
CC(=O)C(Br) 
 
31.  C[allHydrogens=3]-C[allHydrogens=2]-O1-C2[!ring](=O)-C[!aromatic]-C[!aromatic]-C[!aromatic]-
C3[bound(-H) & !aromatic]-C[!ring](=O)-O-C[allHydrogens=2]-C[allHydrogens=3] >> Dieckmann 5-ring 
(symmetry 1)  >> C2[ring]-C3  
 
 
 
 
CCOC(=O)CCCCC(=O)OCC 
 
C[allHydrogens=3]-C[allHydrogens=2]-O-C[!ring](=O)-C2[bound(-H) & !aromatic]-C[!aromatic]-
C[!aromatic]-C[!aromatic]-C3[!ring](=O)-O1-C[allHydrogens=2]-C[allHydrogens=3] >> Dieckmann 5-ring 
(symmetry 2)  >> C2-C3[ring]  
 
 
 
CCOC(=O)CCCCC(=O)OCC 
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32.  C[allHydrogens=3]-C[allHydrogens=2]-O1-C2[!ring](=O)-C[!aromatic]-C[!aromatic]-C[!aromatic]-
C[!aromatic]-C3[bound(-H) & !aromatic]-C[!ring](=O)-O-C[allHydrogens=2]-C[allHydrogens=3] >> 
Dieckmann 6-Ring (symmetry 1)  >> C2-C3   
 
 
 
CCOC(=O)CCCCCC(=O)OCC 
 
C[allHydrogens=3]-C[allHydrogens=2]-O-C[!ring](=O)-C2[bound(-H) & !aromatic]-C[!aromatic]-
C[!aromatic]-C[!aromatic]-C[!aromatic]-C3[!ring](=O)-O1-C[allHydrogens=2]-C[allHydrogens=3] >> 
Dieckmann 6-Ring (symmetry 2)  >> C2-C3 
 
 
CCOC(=O)CCCCCC(=O)OCC 
 
33.  c$1:c:c(-O1[allHydrogens=1]):c(-C(=O)-C2[allHydrogens=3]):c:c$:1 ++ c$1:c:c:c(-C3(=O4)-
Cl5):c[bound(-H)]:c$:1 >> Flavone >> C2=C3-O1 
 
 
 
c1cc(O)c(C(=O)C)cc1    +    c1ccc(C(=O)Cl)cc1 
 
34.  c-C1#N2 ++ C3[allHydrogens=0](=O4)-O5[allHydrogens=1] >> Oxadiazole (charge 1) >> C1$1=N-O-
C3=N2$-1   
 
 
 
c1cc(C#N)ccc1    +    CC(=O)O 
 
c-C1#N2 ++ C3[allHydrogens=0](=O4)-O5[charge=-1] >> Oxadiazole (charge 2) >> C1$1=N-O-C3=N2$-
1 
 
 
 
c1cc(C#N)ccc1    +    CC(=O)[O-] 
 
35.  C(=O)(-*[{O & allHydrogens=0} | C])-C1[allHydrogens=2]-C(=O)-*[{O & allHydrogens=0} | C] ++ 
C2[!aromatic]=C3[!aromatic]-C4(=O)-C >> Michael addition  >> C1-C2-C3-C4 
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CC(=O)CC(=O)C    +    C=CC(=O)C 
 
36.  *[{C & !bound(-H)}|{O & !bound(-H) & charge=0}]-C1[!ring](=O)-O2-C[!ring] ++ C3[allHydrogens=2]-
C(=O)-*[{C & !bound(-H)}|{O & !bound(-H) & charge=0}] >> crossed Claissen  >> C3-C1 
 
 
 
c1ccccc1C(=O)OC    +    CCC(=O)OC 
 
37.  c-O1[allHydrogens=1] ++ C2[allHydrogens=2]-*3[I|Br|Cl] >> Williamson ether  >> O1-C2 
 
 
 
c1cc(O)ccc1    +    CCBr 
 
38.  C-C1(=O2)-C ++ N3[allHydrogens=2 &charge=0]-C[!bound(=O) & !bound(=N)] >> red. amination (one 
step), ketone, prim. amine (charge 1) >> C1-N3[charge=1] 
 
 
 
CC(=O)C    +    CN 
 
C-C1(=O2)-C ++ N3[allHydrogens=3 &charge=1]-C[!bound(=O) & !bound(=N)] >> red. amination  
ketone, prim. amine (charge 2) >> C1-N3[charge=1]   
 
 
 
CC(=O)C    +    C[NH3+] 
 
39.  C-C1[bound(-H)](=O2) ++ N3[allHydrogens=2 &charge=0]-C[!bound(=O) & !bound(=N)] >> red. 
amination, aldehyde, prim. amine (charge 1) >> C1-N3[charge=1]   
 
 
 
CC(=O)    +    CN 
 
C-C1[bound(-H)](=O2) ++ N3[allHydrogens=3 &charge=1]-C[!bound(=O) & !bound(=N)] >> red. 
amination, aldehyde, prim. amine (charge 2)>> C1-N3[charge=1] 
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CC(=O)    +    C[NH3+] 
 
40.  C-C1(=O2)-C ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=1 & charge=0 & !aromatic]-
C[!bound(=O) & !bound(=N)] >> red. amination, ketone, sec. amine (charge 1) >> C1-N3[charge=1] 
 
 
 
CC(=O)C    +    CNC 
C-C1(=O2)-C ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=2 & charge=1 & !aromatic]-
C[!bound(=O) & !bound(=N)] >> red. amination, ketone, sec. amine (charge 2)  >> C1-N3[charge=1] 
 
 
 
CC(=O)C    +    C[NH2+]C 
 
41.  C-C1[bound(-H)](=O2) ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=1 & charge=0 & !aromatic]-
C[!bound(=O) & !bound(=N)] >> red. amination, aldehyde, sec. amine (charge 1) >> C1-N3[charge=1] 
 
 
 
CC(=O)    +    CNC 
 
C-C1[bound(-H)](=O2) ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=2 & charge=1 & !aromatic]-
C[!bound(=O) & !bound(=N)] >> red. amination, aldehyde, sec. amine (charge 2) >> C1-N3[charge=1]
   
 
 
 
CC(=O)    +    C[NH2+]C 
 
42.  C1[sp2]-B3(-O)-O ++ C2[sp2 & !bound(=O)]-*4[Cl|Br|I]>> Suzuki >> C1-C2 
 
 
 
c1cc(B(O)(O))ccc1    +    c1cc(Cl)ccc1 
 
43.  c[allHydrogens=1]$1:c:c:c[allHydrogens=1]:c$2-N[allHydrogens=1]-C=C5[allHydrogens=1]-c$:1$:2 ++ 
C[allHydrogens=2]$3-N-C[allHydrogens=2]-C[allHydrogens=2]-C4(=O7)-C6[allHydrogens=2]$-3 >> 
Piperidine+Indole  >> C4(=C6)-C5   
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c1cc2NC=Cc2cc1    +    C1C(=O)CCNC1 
 
44.  C1[!bound(=O)]-*2[Br|Cl|I] ++ *5[Br|Cl]-C4[allHydrogens=2]-C[allHydrogens=2] >> Negishi >> C1-C4 
   
 
 
 
CI    +    CCBr 
 
45.  C1[bound(-H) & !bound(=O)]-O2[allHydrogens=1] ++ C(=O)-N3[allHydrogens=1]-C(=O) >> Mitsunobu 
(imide) >> C1-N3 
 
 
 
CC(O)C    +    C(=O)NC(=O) 
 
46.  C1[bound(-H) & !bound(=O)]-O2[allHydrogens=1] ++ C-C(=O)-O3[allHydrogens=1] >> Mitsunobu 
Carbonsäure (carbon acid, charge 1)  >> C1-O3 
 
 
 
CC(O)C    +    CC(=O)O 
 
 
C1[bound(-H) & !bound(=O)]-O2[allHydrogens=1] ++ C-C(=O)-O3[charge=-1] >> Mitsunobu (carbon 
acid, charge 2)  >> C1-O3  CC(O)C CC(=O)[O-] 
 
 
47.  C1[bound(-H) & !bound(=O)]-O2[allHydrogens=1] ++ C-N3[bound(-H)]-S(=O)(=O)-C >> Mitsunobu 
Sulfonic amide >> C1-N3 
 
 
 
CC(O)C    +    CNS(=O)(=O)C 
 
48.  C1[!bound(=O)]-*3[Br | I | Cl] ++ C-C2[allHydrogens=1 & !aromatic]=C[!aromatic](-C)-C >> Heck  >> 
C1-C2 
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CBr    +    CC(=CC)C 
 
49.  C-C1(=O)-Cl2 ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=2 & charge=0] >> Amide, prim. amine 
(charge 1) >> C1-N3  
 
 
 
CC(=O)Cl    +    CN 
 
C-C1(=O)-Cl2 ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=3 & charge=1] >> Amide, prim. amine 
(charge 2) >> C1-N3 
 
 
 
CC(=O)Cl    +    C[NH3+] 
 
50.  C-C1(=O)-Cl2 ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=1 & charge=0]-C[!bound(=O) & 
!bound(=N)] >> Amide, sec. amine (charge 1) >> C1-N3  
 
 
 
CC(=O)Cl    +    CNC 
 
C-C1(=O)-Cl2 ++ C[!bound(=O) & !bound(=N)]-N3[allHydrogens=2 & charge=1]-C[!bound(=O) & 
!bound(=N)] >> Amide, sec. amine (charge 2) >> C1-N3 
 
 
 
CC(=O)Cl    +    C[NH2+]C 
 
51.  C-C1(=O)-Cl2 ++ C[!bound(=O)]-O3[allHydrogens=1] >> Ester  >> C1-O3   
 
 
 
CC(=O)Cl    +    CO 
 
52.  c-C1[!aromatic]=C2[!aromatic & allHydrogens=2] ++ S3[allHydrogens=1]-C >> Thioether  >> C1-C2-S3 
 
 
 
c1ccccc1C=C    +    CS 
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53.  C-C1(=O)-Cl2 ++ C3-I4 >> Ketone >> C1-C3 
 
 
 
CC(=O)Cl    +    CI 
 
54.  C-S1(=O)(=O)-Cl3 ++ N2[allHydrogens=2 & charge=0]-C[!bound(=O) & !bound(=N)] >> Sulfonamid 
(Ladung 1) >> S1-N2 
 
 
 
CS(=O)(=O)Cl    +    CN 
 
C-S1(=O)(=O)-Cl3 ++ N2[allHydrogens=3 & charge=1]-C[!bound(=O) & !bound(=N)] >> Sulfonamid 
(Ladung 2) >> S1-N2 
 
 
 
CS(=O)(=O)Cl    +    C[NH3+] 
 
55.  c1-B2(-O[allHydrogens=1])(-O[allHydrogens=1]) ++ c$1:n3[allHydrogens=1]:n:c:c$:1 >> Ar-Pyrazole  >> 
c1-N3   
 
 
 
c1cc(B(O)(O))ccc1    +    C1=CC=NN1 
 
56.  c1-B2(-O[allHydrogens=1])(-O[allHydrogens=1]) ++ c$1:n3[allHydrogens=1]:c:n:c$:1 >> Ar-Imidazole  
>> c1-N3   
 
 
 
c1cc(B(O)(O))ccc1    +    C1=CN=CN1 
 
57.  C1[sp3]-*2[Cl|Br|I] ++ C3[allHydrogens=1]#C >> Alkine alkylation >> C1-C3 
 
 
 
CCl    +    C#C 
 
58.  C-C2(=O)-Cl4 ++ C3[allHydrogens=1]#C >> Alkine acylation  >> C2-C3 
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 ﾠ
Preprocessing Reactions 
 
1.  C1(=O2)-O3[allHydrogens=1] >> FGI Acyl chloride (charge 1) >> C1(=O2)-Cl 
 
 
 
C1(=O2)-O3[charge=-1] >> FGI acyl Chloride (charge 2) >> C1(=O2)-Cl 
 
 
 
2.  C1[aliphatic & !bound(=O) & !bound(=S)]-O2[allHydrogens=1] >> FGI bromination >> C1-Br 
 
 
 
3.  C1[aliphatic & !bound(=O) & !bound(=S)]-O2[allHydrogens=1] >> FGI chlorination >> C1-Cl 
 
 
 
4.  C-S1(=O)(=O)-O2[allHydrogens=1] >> FGI sulfonyl chloride (charge 1)>> S1-Cl  
 
 
 
C-S1(=O)(=O)-O2[charge=-1] >> FGI sulfonyl chloride (charge 2) >> S1-Cl  
 
 
 
5.  C1[!aromatic & allHydrogens=2 & !bound(-Halogen)]-C(=O)-O[allHydrogens=1] >> FGA alpha 
bromination (charge 1) >> C1-Br 
 
 
 
C1[!aromatic & allHydrogens=2 & !bound(-Halogen)]-C(=O)-O[charge=-1] >> FGA alpha bromination 
(charge 2) >> C1-Br 
 
 
 
6.  C1[!aromatic & allHydrogens=2 & !bound(-Halogen)]-C(=O)-O[allHydrogens=1] >> FGA alpha 
chlorination (Ladung 1) >> C1-Cl 
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C1[!aromatic & allHydrogens=2 & !bound(-Halogen)]-C(=O)-O[charge=-1] >> FGA alpha chlorination 
(charge 2) >> C1-Cl 
 
 
7.  c1-*2[Cl|Br] >> FGI Rosenmund-von-Braun >> c1-C#N 
 
 
 
8.  C-C1[allHydrogens=2]-O2[allHydrogens=1] >> FGI nitrilation prim. hydroxy  >> C1#N 
 
 
 
9.  C-C1[allHydrogens=2]-N2[allHydrogens=2 & charge=0] >> FGI nitrilation prim. amine (charge 1) >> 
C1#N2 
 
 
 
C-C1[allHydrogens=2]-N2[allHydrogens=3 & charge=1] >> FGI nitrilation prim. Aminen (charge 2) >> 
C1#N2 
 
 
 
10.  C-C1#C2[allHydrogens=1] >> FGI nitrilation term. alkine >> C1#N 
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Analytical Spectra 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 18: 1H NMR spectrum  Compound 18: mass spectrum 	
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Compound 19: 1H NMR spectrum  Compound 19: mass spectrum 	
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Compound 15: 1H NMR spectrum  Compound 15: mass spectrum 	
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Compound 15: HPLC, UV spectrum 
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Compound 15: 
13C NMR 
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Compound 15: high resolution mass spectrum 
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